Method for production of immunoglobulin single variable domain

JP2024073531A5Active Publication Date: 2024-11-11ABLYNX NV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024038103
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-02-12
Filing Date
2024-03-12
Publication Date
2024-11-11
Estimated Expiration
2037-02-10

AI Technical Summary

Technical Problem

Existing methods for producing immunoglobulin single variable domains, such as VHH1 type, in Pichia pastoris yield significantly lower than expected, posing challenges in therapeutic applications due to insufficient expression and production levels.

Method used

Enhancing the expression of immunoglobulin single variable domains in Pichia pastoris by co-expressing accessory proteins such as PDI1, Kar2p, and HAC1 spliced forms, which significantly increases yield by up to 10-fold.

Benefits of technology

The method achieves substantial yield improvements, allowing for the production of immunoglobulin single variable domains at levels suitable for therapeutic applications, overcoming the limitations of conventional expression systems.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000043_0000
    Figure 00000043_0000
  • Figure 00000057_0000
    Figure 00000057_0000
  • Figure 00000057_0001
    Figure 00000057_0001
Patent Text Reader

Abstract

To provide methods for the production of polypeptides comprising at least one immunoglobulin variable domain that result in an increased yield.SOLUTION: A method for the production of a polypeptide comprising or essentially consisting of at least one immunoglobulin single variable domain is provided, the method comprising the step of expressing, in a Pichia host, the polypeptide and simultaneously enhancing, in the Pichia host, the expression of the auxiliary protein HAC1 spliced type.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to methods for producing immunoglobulin single variable domains. More specifically, the present invention provides improved methods for producing immunoglobulin single variable domains, which result in increased yields. The present invention further provides nucleic acids, genetic constructs and host cells for use in the methods of the invention, as well as immunoglobulin single variable domains obtainable by the methods of the invention.

[0002] Background technology For therapeutic applications, the quality of the antibody or antibody fragment product must be very high. This places high demands on the production process of biological therapeutics. The production costs of these therapeutic compounds are strongly influenced by the difficulties encountered during the production process. Low yields or lack of uniformity will affect the economics of the production process and therefore the cost of the therapeutic drug overall.

[0003] Limitations in obtaining adequate yields of functional products have been reported for conventional immunoglobulins and their fragments in a wide range of expression systems, including in vitro translation, E. coli, yeasts such as Saccharomyces cerevisiae and Pichia pastoris, mammalian cells such as Chinese hamster ovary cells, and the baculovirus system in insect cells. Among other obstacles in antibody expression appear to be an insufficient supply of light chains, improper processing and folding in the endoplasmic reticulum (ER), and intracellular accumulation of heavy chain fragments (Lange et al. 2001, J. Immunol. Methods 255: 103; Gasser et al. 2006, Biotechnol Bioeng. 94: 353; Gach et al. 2007, J. Biotechnol. 128: 735; Jenkins et al. 2009, Biotechnol. Appl. Biochem. 53: 73).

[0004] Intervention in protein folding and secretion pathways has been described as one of the various strategies to improve the expression and quality of recombinant proteins, such as monoclonal antibodies (MAbs). However, overexpression of one or more components of the ER secretion machinery has produced mixed results in terms of improving productivity. Many challenges remain in achieving consistently high yields in the production of biopharmaceuticals (Jenkins et al. 2009, Biotechnol. Appl. Biochem. 53: 73).

[0005] Pichia pastoris has been developed as a host for the production of heterologous proteins. Although this host is known as a highly efficient expression system, the production of particularly complex proteins has been found to show a rather low success rate. In P. pastoris, co-overexpression of immunoglobulin-binding protein (BiP) increased the secretion level of scFv (A33scFv) by about three-fold. In contrast, co-overexpression of protein disulfide isomerase (PDI1) had no obvious effect on the secretion of A33scFv. Co-overexpression of BiP and PDI1 in P. pastoris did not increase the secretion of A33scFv, and the protein level remained the same as in the control strain (Damasceno et al. 2007, Appl. Microbiol. Biotechnol. 74: 381). Compared to the control strain, the productivity of 2F5 Fab fragments in P. pastoris could be improved from 1.2-fold when co-overexpressing with BFR2 to 2.3-fold when overexpressing SSE1 or KIN2 (Gasser et al. 2007, Appl. Environ. Microbiol. 73: 6499). Overexpression of the basic leucine zipper (bZIP) transcription factor HAC1 had only a minor effect (1.3-fold) on the secretion of Mab 2F5 Fab fragments in P. pastoris, whereas overexpression of PDI1 allowed a 1.9-fold increase in Fab levels (Gasser et al. 2006, Biotechnol Bioeng. 94: 353). The authors conclude that a sufficient supply of light chains and the formation of interchain disulfide bonds can be recognized as the main rate-limiting factors for the assembly and subsequent secretion of Fabs.

[0006] In contrast to these difficulties observed with conventional four-chain antibodies or fragments thereof (including Fab and scFv), immunoglobulin single variable domains are known to be easily expressed and secreted at sufficient rates and levels from hosts such as E. coli and P. pastoris. Immunoglobulin single variable domains do not have interchain disulfide bridges and are characterized by the formation of an antigen-binding site by a single immunoglobulin variable domain, which does not require interactions with additional domains (e.g., in the form of VH / VL interactions) for antigen recognition. The production of nanobodies, as one embodiment of immunoglobulin single variable domains, in prokaryotic hosts such as E. coli, has been extensively described (see, for example, Ghahroudi et al. 1997, FEBS Letters 414: 521-526; Muyldermans 2001, J. Biotechnol. 74: 277-302; Vranken et al. 2002, Biochemistry 41: 8570-8579).

[0007] The production of nanobodies in lower eukaryotic hosts such as P. pastoris is described in Frenken et al. 2000 (J. Biotechnol. 78: 11-21), WO 94 / 25591, WO 2010 / 125187, WO 2012 / 056000 and WO 2012 / 152823.

[0008] Recombinant camelid single variable domains are routinely obtained at levels of 5-10 mg / l when expressed in E. coli grown in shake culture flasks without any optimization of conditions (Ghahroudi et al. 1997). It is even possible to obtain higher yields of VHH expression using other expression systems. Production levels of 9.3 mg / l / OD660 or about 250 mg of secreted protein per liter of Saccharomyces yeast culture in shake flasks have been described by Frenken et al. 2000. More recently, nanobody yields of over 1 g per liter have been described upon expression in P. pastoris (WO 2010 / 139808; WO 2012 / 152823).

[0009] WO 2010 / 125187 describes a method for producing single variable domains in yeast (e.g., P. pastoris). The method of WO 2010 / 125187 applies conditions that promote the formation of disulfide bridges in the single variable domains. One of the conditions proposed is the enhanced expression of thiol isomerase (e.g., PDI1).

[0010] The fact that fully functional immunoglobulin single variable domains can be readily produced at sufficient rates and levels in, for example, E. coli or yeast represents a significant advantage of this immunoglobulin format over conventional immunoglobulins.

[0011] Summary of the Invention VHHs and nanobodies can be expressed using expression systems described in the art for their expression (WO 1994 / 25591; Ghahroudi et al. 1997, FEBS Letters 414: 521-526; Frenken et al. 2000, J. Biotechnol. 78: 11-21; Muyldermans 2001, J. Biotechnol. 74: 277-302; Vranken et al. 2002, Biochemistry 41: 8570-8579; WO 2010 / 125187; WO 2012 / 056000; WO 2012 / 152823 and Ablynx). NV), the inventors have found that in some cases (e.g. multivalent VHHs and nanobodies and / or VHHs and nanobodies with more than one disulfide bridge) the expression of VHHs and nanobodies is more challenging, resulting in expression levels and / or yields much lower than expected. For example, the inventors have unexpectedly observed problems with the production of some therapeutic VHH1-type immunoglobulin single variable domains. Upon expression of these immunoglobulin single variable domains in P. pastoris, the inventors obtained these immunoglobulin single variable domains in much lower yields compared to the yields normally obtained with VHH2-type and VHH3-type immunoglobulin single variable domains. In contrast to what has been established for immunoglobulin single variable domains, the expression of certain immunoglobulin single variable domains in P. pastoris, such as, for example, immunoglobulin single variable domains of the VHH1 type, did not result in significant amounts of functional product.

[0012] The inventors have provided a solution to this problem, as further shown herein. Moreover, the inventors have observed that the proposed solution for improving the yield of immunoglobulin single variable domains is generally applicable, i.e. not only for improving the yield of immunoglobulin single variable domains of the VHH1 type, but also for improving the yield of other immunoglobulin single variable domains, such as immunoglobulin single variable domains of the VHH2 and VHH3 type.

[0013] Thus, in one aspect, the present invention relates to the observation of low yields upon expression of certain immunoglobulin single variable domains in P. pastoris.

[0014] In a further aspect of the invention, methods for the production of immunoglobulin single variable domains are provided, which increase the yield of the product obtained. These methods are also referred to herein as "method(s) of the invention". Thus, the present invention also provides methods for the production of immunoglobulin single variable domains that overcome this unexpected problem. More particularly, the inventors have discovered (by screening a library of accessory proteins) that enhanced expression of certain accessory proteins (PDI1 (SEQ ID NO: 5), Kar2p (SEQ ID NO: 4), RPP0 (SEQ ID NO: 6), particularly the HAC1 splice form (SEQ ID NO: 14)) in a Pichia host increased the yield of immunoglobulin single variable domains when expressed in said Pichia host. Increases in yield of more than 2-fold to more than 10-fold (and even more) were obtained.

[0015] In one aspect, the invention therefore relates to a method for increasing the expression and / or production yield of an immunoglobulin single variable domain in Pichia (e.g. P. pastoris), in which an immunoglobulin single variable domain is expressed, but at the same time the expression of the HAC1 splice form is also enhanced.

[0016] The immunoglobulin single variable domains used in the methods of the invention may form part of a polypeptide (also referred to as a "polypeptide of the invention"), which may comprise or consist essentially of one or more (i.e. at least one) immunoglobulin single variable domains, and may optionally further comprise one or more further amino acid sequences (all optionally linked via one or more suitable linkers).

[0017] Thus, the invention provides a method for producing a polypeptide (herein referred to as a "polypeptide of the invention") comprising or consisting essentially of at least one immunoglobulin single variable domain in a Pichia host (e.g., P. pastoris), the method comprising the steps of expressing a polypeptide of the invention in a Pichia host, and enhancing expression of a HAC1 splice form protein in said Pichia host. The method of the invention may further comprise the step of isolating and / or purifying the polypeptide of the invention.

[0018] The method of the invention is particularly suitable for immunoglobulin single variable domains and polypeptides of the invention which are not easily expressible in Pichia (e.g. P. pastoris) or which are expressed in very low yields when expressed under standard conditions (as further defined herein), such that expression of these immunoglobulin single variable domains or polypeptides of the invention in Pichia (e.g. P. pastoris) does not result in sufficient amounts of immunoglobulin single variable domains and / or polypeptides. Thus, in one embodiment, the immunoglobulin single variable domains and / or polypeptides of the invention are selected from immunoglobulin single variable domains and / or polypeptides which, when expressed in a Pichia host (e.g. P. pastoris) under standard Pichia expression conditions (as further defined herein), give yields of 0.5 g / l or less, such as 0.4 g / L, 0.3 g / L, 0.2 g / L, 0.1 g / L, 0.05 g / L, 0.01 g / L or even less. In another embodiment, the immunoglobulin single variable domains and / or polypeptides of the invention are selected from immunoglobulin single variable domains and / or polypeptides for which the yield obtained when expressed in a Pichia host (e.g. P. pastoris) under Pichia expression conditions (as further defined herein) shows an inverse correlation (as further defined herein) with the copy number of the nucleic acid encoding said immunoglobulin single variable domains and / or polypeptides.

[0019] In a specific embodiment of the invention, the method of the invention is particularly suited for immunoglobulin single variable domains and polypeptides of the invention that are readily expressible in Pichia, such as P. pastoris. Thus, in one embodiment, the immunoglobulin single variable domains and / or polypeptides of the invention are selected from immunoglobulin single variable domains and / or polypeptides that, when expressed in a Pichia host (e.g. P. pastoris) under Pichia expression conditions (as further defined herein), give a yield of 0.5 g / l or more, such as 1 g / L, 2 g / L, 3 g / L, 4 g / L, 5 g / L, 6 g / L or even more.

[0020] In the above methods, the polypeptide of the invention may comprise or essentially consist of two or more immunoglobulin single variable domains. Such polypeptides are also referred to as multivalent polypeptides. Thus, in a specific embodiment, the polypeptide of the invention to be expressed by the method of the invention is a multivalent polypeptide.

[0021] Alternatively, the polypeptide expressed by the method of the invention may comprise or consist essentially of one immunoglobulin single variable domain. Such polypeptides will also be referred to herein as monovalent polypeptides. Thus, in another specific embodiment, the polypeptide of the invention to be expressed by the method of the invention is a monovalent polypeptide.

[0022] In the above methods, the immunoglobulin single variable domain (which may be present in a polypeptide of the invention) may be (but is not limited to) an immunoglobulin single variable domain which is a light chain variable domain or a heavy chain variable domain, more particularly a heavy chain variable domain derived from a traditional four-chain antibody or a heavy chain variable domain derived from a heavy chain antibody, in particular a domain antibody (or an amino acid sequence suitable for use as a domain antibody), a single domain antibody (or an amino acid sequence suitable for use as a single domain antibody), a "dAb" (or an amino acid sequence suitable for use as a dAb) or a nanobody (including but not limited to VHH sequences), preferably a nanobody.

[0023] In a preferred embodiment, the Nanobodies expressed in the methods of the invention are VHH sequences (VHH), (partially) humanized VHH sequences (humanized VHH), camelized heavy chain variable domains (camelized VH) or Nanobodies obtained by techniques such as affinity maturation.

[0024] In another specific embodiment of the invention, the immunoglobulin single variable domain expressed in the method of the invention (possibly present in the polypeptide of the invention) comprises at least two disulfide bridges. In another specific embodiment, the immunoglobulin single variable domain belongs to the group of VHH1 type immunoglobulin single variable domains.

[0025] In another embodiment, the immunoglobulin single variable domain (which may be present in the polypeptide of the invention) does not belong to the group of VHH1 type immunoglobulin single variable domains, but to another group of immunoglobulin single variable domains, such as VHH2, VHH3 or any other type of immunoglobulin single variable domain.

[0026] In yet another specific embodiment, the immunoglobulin single variable domains expressed in the methods of the invention (which may be present in the polypeptides of the invention), such as those described in WO 2012 / 042026 and WO 2013 / 045707, specifically bind c-Met. Thus, polypeptides of the invention comprising at least one immunoglobulin single variable domain that specifically binds c-Met, said immunoglobulin single variable domain comprising two disulfide bridges, form a specific, but non-limiting, aspect of the invention. A particular Nanobody for use in the methods of the invention is SEQ ID NO: 49.

[0027] In a preferred embodiment, one or more of the immunoglobulin single variable domain(s) expressed in the methods of the invention (which may be present in the polypeptides of the invention), such as the immunoglobulin single variable domains described in US Provisional Application US62 / 254,375 to Ablynx NV (see also PCT / EP2016 / 077595), specifically binds TNF.

[0028] Thus, polypeptides of the invention comprising one or more (at least one) immunoglobulin single variable domains that specifically bind to TNF form a particular, non-limiting embodiment of the invention.

[0029] In a specific embodiment, the polypeptide of the invention expressed in the method of the invention comprises or consists essentially of one immunoglobulin single variable domain. Such a polypeptide will also be referred to herein as a monovalent polypeptide. Thus, in a preferred embodiment, in the method of the invention, the polypeptide is a monovalent polypeptide.

[0030] Such a monovalent polypeptide comprising or essentially consisting of one immunoglobulin single variable domain may comprise at least two disulfide bridges. Thus, the immunoglobulin single variable domain that specifically binds to TNF belongs to the VHH1 type immunoglobulin single variable domains.

[0031] Alternatively, the immunoglobulin single variable domain comprises one disulfide bridge.Thus, in a preferred embodiment, the immunoglobulin single variable domain which specifically binds to TNF does not belong to the group of VHH1 type immunoglobulin single variable domains, but to another group of immunoglobulin single variable domains, such as VHH2, VHH3 or any other type of immunoglobulin single variable domain.

[0032] In a preferred embodiment, in the method of the invention, the immunoglobulin single variable domain essentially consists of four framework regions (FR1 to FR4, respectively) and three complementarity determining regions (CDR1 to CDR3, respectively), where CDR1 is SEQ ID NO: 58, CDR2 is SEQ ID NO: 60 and CDR3 is SEQ ID NO: 62.

[0033] Particular Nanobodies for use in the methods of the present invention are selected from the group consisting of SEQ ID NOs: 55 and 56.

[0034] A polypeptide of the invention comprising or consisting essentially of one or more immunoglobulin single variable domains may further comprise one or more other residues or binding units, optionally linked via one or more peptide linkers.

[0035] In one aspect, said one or more other residues may be effective to prevent or reduce binding of antibodies already present in the serum (so-called "pre-existing antibodies") to a polypeptide of the invention (as further described herein).

[0036] In another embodiment, the one or more other moieties or binding units may also be selected from the group consisting of an immunoglobulin single variable domain, a domain antibody, an amino acid sequence suitable for use as a domain antibody, a single domain antibody, an amino acid sequence suitable for use as a single domain antibody, a "dAb", an amino acid sequence suitable for use as a dAb, or a nanobody. Polypeptides comprising or consisting essentially of two or more binding units are also referred to as multivalent constructs.

[0037] In a specific embodiment of the invention, the polypeptide comprising or consisting essentially of one or more immunoglobulin single variable domains expressed in the methods of the invention is a multivalent construct.

[0038] In another specific embodiment, the polypeptide of the invention is a bivalent, trivalent, or tetravalent polypeptide.

[0039] In certain aspects of the present invention, the one or more other binding units may provide the polypeptide of the present invention with an extended half-life compared to a polypeptide not comprising the one or more other binding units. Without being limited thereto, the one or more other binding units providing the polypeptide with an extended half-life may be selected from the group consisting of binding units capable of binding to serum albumin (e.g., human serum albumin) or serum immunoglobulin (e.g., IgG).

[0040] In the methods of the invention, expression of the HAC1 splice form may be enhanced by introduction into the Pichia host of one or more nucleic acid(s) encoding the HAC1 splice form protein. In another embodiment, expression of the HAC1 splice form protein may be enhanced by introduction into the Pichia host of one or more strong promoter(s) controlling expression of the nucleic acid(s) encoding the HAC1 splice form protein.

[0041] The polypeptide comprising or essentially consisting of at least one immunoglobulin single variable domain and the HAC1 splice-form protein may be expressed from the same genetic construct. In this particular embodiment of the invention, the transcription of the nucleic acid encoding the polypeptide comprising or essentially consisting of at least one immunoglobulin single variable domain and the transcription of the nucleic acid encoding the HAC1 splice-form protein may be controlled by the same promoter or by different promoters. The nucleic acid encoding the HAC1 splice-form protein may be located on a genetic construct downstream of the nucleic acid encoding the polypeptide comprising or essentially consisting of at least one immunoglobulin single variable domain. Alternatively, the nucleic acid encoding the polypeptide comprising or essentially consisting of at least one immunoglobulin single variable domain may be located on a genetic construct downstream of the nucleic acid encoding the HAC1 splice-form protein.

[0042] In another embodiment of the invention, the polypeptide comprising or essentially consisting of at least one immunoglobulin single variable domain and the HAC1 splice form protein may be expressed from different genetic constructs. In this particular embodiment of the invention, the transcription of the nucleic acid encoding the polypeptide comprising or essentially consisting of at least one immunoglobulin single variable domain and the transcription of the nucleic acid encoding the HAC1 splice form protein from different genetic constructs may be controlled by two separate promoters which may be the same or different.

[0043] The polypeptide comprising or essentially consisting of at least one immunoglobulin single variable domain and / or the HAC1 splice form protein can also be expressed from a chromosome. In this particular embodiment, expression of the HAC1 splice form protein can be enhanced by introduction of a strong promoter into the chromosome of the Pichia host. Alternatively, one or more nucleic acids encoding the HAC1 splice form protein controlled by a strong promoter may be introduced into the chromosome of the Pichia host. Also, one or more nucleic acids encoding a polypeptide comprising or essentially consisting of at least one immunoglobulin single variable domain may be introduced into the chromosome of the Pichia host.

[0044] In one embodiment of the invention, the number of nucleic acid(s) encoding a polypeptide comprising or consisting essentially of an immunoglobulin single variable domain is 1. In another embodiment of the invention, the number of nucleic acid(s) encoding a polypeptide comprising or consisting essentially of an immunoglobulin single variable domain is 2 or more.

[0045] In another aspect, the present invention also relates to a nucleic acid encoding a polypeptide of the invention (or a suitable fragment thereof) and encoding a HAC1 splice form protein. Such a nucleic acid is also referred to herein as a "nucleic acid of the invention" and may, for example, be in the form of a genetic construct as further described herein.

[0046] Thus, the present invention also relates to a nucleic acid of the present invention in the form of a genetic construct. Such a genetic construct is also referred to herein as a "genetic construct of the present invention" and therefore comprises a nucleic acid encoding a polypeptide of the present invention and a nucleic acid encoding a HAC1 splice form protein. In a specific embodiment, in such a genetic construct of the present invention, the nucleic acid encoding the HAC1 splice form protein is located downstream of the nucleic acid encoding the polypeptide of the present invention. In another specific embodiment, in such a genetic construct of the present invention, the nucleic acid encoding the polypeptide of the present invention is located downstream of the nucleic acid encoding the HAC1 splice form protein. In the genetic construct of the present invention, the expression of the nucleic acid encoding the polypeptide of the present invention and the expression of the nucleic acid encoding the HAC1 splice form protein can be controlled by the same promoter or by different promoters. The promoter may be a constitutive or an inducible promoter.

[0047] In one embodiment of the invention, the copy number of the nucleic acid encoding the polypeptide of the invention is 1. In another embodiment of the invention, the copy number of the nucleic acid encoding the polypeptide of the invention is 2 or more.

[0048] In one embodiment of the invention, the number of auxiliary proteins is one, and the auxiliary protein is the HAC1 splice form. In another embodiment of the invention, the expression of one or more auxiliary proteins is enhanced. In yet another embodiment of the invention, the additional auxiliary protein(s) is / are selected from PDI1, Kar2p, and RPP0. In yet another embodiment of the invention, the number of auxiliary proteins is two. In yet another embodiment of the invention, the number of auxiliary proteins is more than two, for example three or more. In yet another embodiment, the two or more auxiliary proteins are selected from the following combinations of auxiliary proteins: -PDI1 and HAC1 splice forms; -Kar2p and HAC1 splice forms; -RPP0 and HAC1 splice types; -PDI1, Kar2p and HAC1 splice forms; -PDI1, RPP0 and HAC1 splice forms; -Kar2p, RPP0 and HAC1 splice forms; and -PDI1, Kar2p, RPP0 and HAC1 splice forms.

[0049] In a preferred embodiment, the expression of the following accessory proteins is enhanced: -PDI1, Kar2p and HAC1 splice forms; or -Kar2p, RPP0 and HAC1 splice forms.

[0050] In a preferred embodiment of the invention, the accessory protein is the HAC1 splice form (SEQ ID NO: 14).

[0051] In another preferred embodiment, the additional accessory protein is selected from PDI1 (SEQ ID NO:5), Kar2p (SEQ ID NO:4), RPP0 (SEQ ID NO:6), and the HAC1 splice form (SEQ ID NO:14).

[0052] In another preferred embodiment, the two or more auxiliary proteins are selected from the following combinations of auxiliary proteins: - PDI1 (SEQ ID NO: 5) and Hac1 splice form (SEQ ID NO: 14); - Kar2p (SEQ ID NO: 4) and Hac1 splice form (SEQ ID NO: 14); -RPP0 (SEQ ID NO: 6) and Hac1 splice form (SEQ ID NO: 14); - PDI1 (SEQ ID NO: 5), Kar2p (SEQ ID NO: 4) and Hac1 splice form (SEQ ID NO: 14); - PDI1 (SEQ ID NO: 5), RPP0 (SEQ ID NO: 6) and Hac1 splice form (SEQ ID NO: 14); - Kar2p (SEQ ID NO: 4), RPP0 (SEQ ID NO: 6) and Hac1 splice form (SEQ ID NO: 14); and - PDI1 (SEQ ID NO: 5), Kar2p (SEQ ID NO: 4), RPP0 (SEQ ID NO: 6) and Hac1 splice form (SEQ ID NO: 14).

[0053] In another aspect, the invention relates to the introduction of the nucleic acids and genetic constructs of the invention into a Pichia host, also referred to herein as the "Pichia host of the invention". In addition to the transformation of the Pichia host with a plasmid or vector, the transformation of the chromosome of the Pichia host is also encompassed by the invention. A strong (inducible) promoter (in place of the native promoter of the native accessory protein) may be introduced into the chromosome of the Pichia host; or another copy of the accessory protein gene sequence under the control of another (strong) promoter may be introduced into the chromosome.

[0054] In another aspect, the invention relates to a Pichia host which expresses (or is capable of expressing under appropriate circumstances) a polypeptide of the invention (wherein expression of the HAC1 splice form is enhanced); and / or contains a nucleic acid of the invention and / or a genetic construct of the invention.

[0055] In a preferred embodiment, the Pichia host is Pichia pastoris.

[0056] In another preferred embodiment, the Pichia pastoris strain is selected from Pichia pastoris X33 and Pichia pastoris NRRL Y-11430.

[0057] The present invention further relates to methods for the preparation of the nucleic acids of the invention, the genetic constructs of the invention, and the Pichia hosts of the invention; and to the use of said nucleic acids of the invention, the genetic constructs of the invention, and the Pichia hosts of the invention for the production of immunoglobulin single variable domains and polypeptides comprising same.

[0058] The present invention further relates to polypeptides and / or immunoglobulin single variable domains obtainable by any of the methods presented herein, to pharmaceutical and other compositions comprising such polypeptides and / or immunoglobulin single variable domains, and to therapeutic uses of the polypeptides and / or immunoglobulin single variable domains or to methods of treatment involving the use of the polypeptides and / or immunoglobulin single variable domains. [Brief description of the drawings]

[0059] [Figure 1] Nanobody A was expressed in two different Pichia clones generated as described in example 1.2. One Pichia clone contained one copy of the Nanobody A expression cassette in the genome. The second clone contained more than one copy of the Nanobody A expression cassette inserted in the genome. Equal volumes of supernatant from the different clones were compared on SDS-PAGE gels. Densitometric analysis for relative quantification to the band corresponding to the intact Nanobody product was performed. Quantification of band volumes was performed using Imagequant software (GE Healthcare). An inverse correlation between copy number and yield was observed. [Diagram 2] Clones transformed with Nanobody A and the auxiliary protein library were tested for improved expression levels of Nanobody A. Equal volumes of supernatants from different clones were compared on SDS-PAGE gels. Densitometric analysis for relative quantification to the band corresponding to the intact Nanobody product was performed. Quantification of band volumes was performed using Imagequant software (GE Healthcare). Four clones (6H1, 4C2, 5A6, 9C4) were found to secrete significantly higher levels of Nanobody A in shake flasks compared to their corresponding reference clones without auxiliary proteins (Ref copy number = 1 and Ref copy number > 1). Ref: Reference clone with the indicated copy number of the Nanobody A expression cassette inserted in the genome. [Diagram 3]Expression in shake flasks of reference clones carrying more than one copy of the Nanobody A expression cassette transformed with one of the auxiliary proteins Kar2p, RPP0, Hac1 splice variants, or PDI1. Nanobody yields were analyzed on SDS-PAGE and compared to the nanobody yield of the reference clone (without auxiliary proteins). Densitometric analysis for relative quantification to the band corresponding to the intact nanobody product was performed. Quantification of band volumes was performed using Imagequant software (GE Healthcare).

[0060] Detailed Description of the Invention definition Unless otherwise indicated or defined, all terms used have their ordinary meaning in the art, which will be apparent to those of ordinary skill in the art. For example, see standard handbooks, such as Sambrook et al. 1989 (Molecular Cloning: A Laboratory Manual, 2 nd Ed., Vols. 1-3, Cold Spring Harbor Laboratory Press), Ausubel et al. 1987 (Current protocols in molecular biology, Green Publishing and Wiley Interscience, New York), Lewin 1985 (Genes II, John Wiley & Sons, New York, NY), Old et al. 1981 (Principles of Gene Manipulation: An Introduction to Genetic Engineering, 2) nd Ed., University of California Press, Berkeley, CA), Roitt et al. 2001 (Immunology, 6 thEd., Mosby / Elsevier, Edinburgh), Roitt et al. 2001 (Roitt's Essential Immunology, 10 th Ed., Blackwell Publishing, UK) and Janeway et al. 2005 (Immunobiology, 6 th Ed., Garland Science Publishing / Churchill Livingstone, New York), as well as the general background art cited therein.

[0061] Unless otherwise specified, all methods, steps, techniques and operations that are not specifically detailed can and have been carried out in a manner known per se, as will be clear to those skilled in the art.For example, again, reference is made to the standard handbooks and the general background art described herein, as well as the further literature cited therein; and the following reviews, which describe techniques for protein engineering, such as affinity maturation, and other techniques for improving the specificity and other desired properties of proteins, such as immunoglobulins: Presta 2006 (Adv. Drug Deliv. Rev. 58: 640), Levin and Weiss 2006 (Mol. Biosyst. 2: 49), Irving et al. 2001 (J. Immunol. Methods 248: 31), Schmitz et al. 2000 (Placenta 21 Suppl. A: S106), Gonzales et al. 2005 (Tumour Biol. 26: 31).

[0062] When a nucleotide sequence or amino acid sequence is said to "comprise" or "consist essentially of" another nucleotide sequence or amino acid sequence, respectively, this can mean that the latter nucleotide sequence or amino acid sequence has been incorporated into the first described nucleotide sequence or amino acid sequence, respectively, but usually this generally means that the first described nucleotide sequence or amino acid sequence contains within its sequence a chain of nucleotide residues or a chain of amino acid residues, respectively, which has the same nucleotide sequence or amino acid sequence, respectively, as the latter sequence, irrespective of how the first described sequence was actually made or obtained (which may for example be by any suitable method as described herein). By way of non-limiting example, when a polypeptide of the invention is said to comprise an immunoglobulin single variable domain, this can mean that an immunoglobulin single variable domain sequence has been incorporated into the polypeptide sequence of the invention, but usually this generally means that a polypeptide of the invention contains within its sequence a sequence of an immunoglobulin single variable domain, irrespective of how said polypeptide of the invention was made or obtained. Also, when a nucleic acid or nucleotide sequence is said to comprise another nucleotide sequence, the first described nucleic acid or nucleotide sequence is preferably such that, when it is expressed into an expression product (e.g. a polypeptide), the amino acid sequence encoded by the latter nucleotide sequence forms part of the expression product (in other words, the latter nucleotide sequence is in the same reading frame as the larger nucleic acid or nucleotide sequence first described).

[0063] By "substantially consisting of" it is meant that the immunoglobulin single variable domain used in the methods of the invention is either exactly the same as a polypeptide of the invention or corresponds to a polypeptide of the invention having a small number of amino acid residues, for example 1-20 amino acid residues, for example 1-10 amino acid residues, preferably 1-6 amino acid residues, for example 1, 2, 3, 4, 5 or 6 amino acid residues, added to the amino terminus, the carboxy terminus, or both the amino terminus and the carboxy terminus of the immunoglobulin single variable domain.

[0064] A nucleic acid or amino acid is considered to be "(substantially) isolated" when it is separated from at least one other component that is normally associated with it in the source or medium, such as another nucleic acid, another protein / polypeptide, another biological component or macromolecule, or at least one contaminant, impurity, or minor component, for example, as compared to the reaction or culture medium from which it was obtained. In particular, a nucleic acid or amino acid is considered to be "(substantially) isolated" when it is purified at least 2-fold, in particular at least 10-fold, more particularly at least 100-fold, and up to 1000-fold or more. A nucleic acid or amino acid in "(substantially) isolated form" is preferably substantially homogeneous, as determined using a suitable technique, such as a suitable chromatographic technique, for example polyacrylamide gel electrophoresis.

[0065] The term "expression of" or "expressing" a polypeptide, such as an immunoglobulin single variable domain and / or polypeptide of the invention or an auxiliary protein, is the process by which information from a gene is used to synthesize a functional gene product (i.e., an immunoglobulin single variable domain and / or polypeptide of the invention or an auxiliary protein). When an auxiliary protein or polypeptide, such as an immunoglobulin single variable domain and / or polypeptide of the invention, is said to be "expressed from" a nucleic acid, a genetic construct, or a chromosome, it is synthesized through a process by which information from a nucleic acid, a genetic construct, or a chromosome is used to synthesize a functional gene product (i.e., an immunoglobulin single variable domain and / or polypeptide of the invention or an auxiliary protein). When proteins are said to be "co-expressed", the proteins are expressed simultaneously. "Enhancing expression" of a gene means that the production of a gene product (e.g., an auxiliary protein) is increased compared to the production of the gene product without enhanced gene expression. As further explained, expression of a particular gene can be enhanced by various means, including the use of appropriate control sequences, such as a strong promoter, and / or increasing the amount of the gene, for example by increasing the copy number of the respective gene.

[0066] The term "yield" as used herein relates to the amount of immunoglobulin single variable domains and / or polypeptides of the invention produced in functional form when expressed in a Pichia host, and is expressed as g (grams) of immunoglobulin single variable domains and / or polypeptides of the invention per L (liter) of culture medium.

[0067] Immunoglobulin Single Variable Domains Unless otherwise specified, the term "immunoglobulin sequence", whether used herein to refer to a heavy chain antibody or a traditional four chain antibody, refers to a full size antibody, its individual chains, as well as any portion thereof, domain thereof, or fragment thereof (such as an antigen binding domain or fragment, e.g., the V HHDomain or V H / V L In addition, the term "immunoglobulin sequence," "antibody sequence," "variable domain sequence," "V domain," and the like are used herein as a general term that includes both the immunoglobulin sequence and the antibody sequence (e.g., "immunoglobulin sequence," "antibody sequence," "variable domain sequence," "V domain," and the like. HH The term "sequence" as used herein (in terms such as "sequence" or "protein sequence") should be generally understood to include both the related amino acid sequence as well as the nucleic acid or nucleotide sequence encoding it, unless the context requires a more restrictive interpretation.

[0068] The term "immunoglobulin single variable domain", which is used interchangeably with "single variable domain", defines a molecule in which an antigen-binding site resides on and is formed by a single immunoglobulin domain. This distinguishes immunoglobulin single variable domains from "conventional" immunoglobulins or fragments thereof (e.g. Fab, scFv, etc.), in which two immunoglobulin domains, in particular two variable domains, interact to form the antigen-binding site. Typically, in conventional immunoglobulins, a heavy chain variable domain (VH) and a light chain variable domain (VL) interact to form the antigen-binding site. In this case, the complementarity determining regions (CDRs) of both VH and VL contribute to the antigen-binding site, i.e. a total of six CDRs will be involved in forming the antigen-binding site.

[0069] In contrast, the binding site of an immunoglobulin single variable domain is formed by a single VH or VL domain. The antigen-binding site of an immunoglobulin single variable domain is therefore formed by no more than three CDRs.

[0070] Thus, the terms "immunoglobulin single variable domain" and "single variable domain" do not include conventional immunoglobulins or fragments thereof which require the interaction of at least two variable domains for the formation of an antigen-binding site. These terms do, however, include fragments of conventional immunoglobulins in which the antigen-binding site is formed by a single variable domain.

[0071] Typically, a single variable domain will be an amino acid sequence consisting essentially of the four framework regions (FR1 to FR4, respectively) and the three complementarity determining regions (CDR1 to CDR3, respectively); or any suitable fragment of such an amino acid sequence (which will thus usually contain at least some of the amino acid residues forming at least one of the CDRs). Such single variable domains and fragments are most preferably such that they comprise an immunoglobulin fold or are capable of forming an immunoglobulin fold under suitable conditions. Thus, a single variable domain may comprise, for example, a light chain variable domain sequence (e.g. a VL sequence) or a suitable fragment thereof; or a heavy chain variable domain sequence (e.g. a VH sequence or a VHH sequence) or a suitable fragment thereof; as long as it is capable of forming a single antigen-binding unit (i.e. a functional antigen-binding unit consisting essentially of a single variable domain, such that the single antigen-binding domain does not need to interact with another variable domain to form a functional antigen-binding unit, as is the case for example for variable domains present in conventional antibodies and scFv fragments, which need to interact with another variable domain, e.g. through VH / VL interactions, to form a functional antigen-binding domain).

[0072] In one embodiment of the invention, the immunoglobulin single variable domain is a light chain variable domain sequence (e.g. a VL sequence) or a heavy chain variable domain sequence (e.g. a VH sequence); more specifically, the immunoglobulin single variable domain may be a heavy chain variable domain sequence derived from a traditional four-chain antibody, or a heavy chain variable domain sequence derived from a heavy chain antibody.

[0073] For example, a single variable domain or immunoglobulin single variable domain (or amino acids suitable for use as an immunoglobulin single variable domain) may be a (single) domain antibody (or amino acids suitable for use as a (single) domain antibody), a "dAb" or dAb (or amino acids suitable for use as a dAb), or a nanobody (as defined herein, including but not limited to a VHH); other single variable domains, or any suitable fragment of any one of them. For a general description of (single) domain antibodies, reference is made to the prior art cited herein, as well as to EP Patent No. 0 368 684. For the term "dAb" see, for example, Ward et al. 1989 (Nature 341: 544), Holt et al. 2003 (Trends Biotechnol. 21: 484), as well as, for example, WO 04 / 068820, WO 06 / 030220, WO 06 / 003388 and other published patent applications of Domantis Ltd. It should also be noted that single variable domains may be derived from certain species of sharks (e.g. the so-called "IgNAR domains", see, for example, WO 05 / 18629), although these are less preferred in the context of the present invention as they are not of mammalian origin.

[0074] In particular, the immunoglobulin single variable domain may be a Nanobody (as defined herein) or a suitable fragment thereof. [Note: Nanobody, Nanobodies and Nanoclone are registered trademarks of Ablynx NV]. For a general description of Nanobodies, reference is made to the prior art cited herein, e.g. WO 08 / 020079 (page 16).

[0075] The amino acid sequence and structure of immunoglobulin sequences, and in particular Nanobodies, can be considered to be composed of four framework regions or "FRs", referred to in the art and herein as, but not limited to, "framework region 1" or "FR1", "framework region 2" or "FR2", "framework region 3" or "FR3", and "framework region 4" or "FR4", respectively; which framework regions are interrupted by three complementarity determining regions or "CDRs", referred to in the art as "complementarity determining region 1" or "CDR1", "complementarity determining region 2" or "CDR2", and "complementarity determining region 3" or "CDR3", respectively.

[0076] The total number of amino acid residues in a Nanobody may be in the region of 110-120, preferably 112-115, and most preferably 113. However, parts, fragments, analogues or derivatives of Nanobodies (as further described herein) are not particularly limited with respect to their length and / or size, so long as such parts, fragments, analogues or derivatives meet the further requirements outlined herein, and are also preferably suitable for the purposes described herein.

[0077] For a further description of VHHs and nanobodies see the review article by Muyldermans 2001 (Rev. Mol. Biotechnol. 74: 277) and the following patent applications which are mentioned as general background art: Brussel, WO 94 / 04678, WO 95 / 04079 and WO 96 / 34103; Unilever AG, WO 94 / 25591, WO 99 / 37681, WO 00 / 40968, WO 00 / 43507, WO 00 / 65057, WO 01 / 40310, WO 01 / 44301, EP 1 134 231 and WO 02 / 48193; Vlaams Instituut voor Biotechnologie (VIB) in International Publication Nos. WO 97 / 49805, WO 01 / 21817, WO 03 / 035694, WO 03 / 054016, and WO 03 / 055527; WO 03 / 050531 to Algonomics NV and Ablynx NV; WO 01 / 90190 by the National Research Council of Canada; WO 03 / 025020 (=European Patent No. 1433793) by the Institute of Antibodies; and Ablynx Reference is made to WO 04 / 041867, WO 04 / 041862, WO 04 / 041865, WO 04 / 041863, WO 04 / 062551, WO 05 / 044858, WO 06 / 40153, WO 06 / 079372, WO 06 / 122786, WO 06 / 122787 and WO 06 / 122825 by Ablynx NV, as well as further published patent applications by Ablynx NV. Reference is also made to further prior art described in these applications, in particular the list of documents set out on pages 41-43 of International Application WO 06 / 040153, which list and documents are incorporated herein by reference.As described in these documents, Nanobodies (especially VHHs and partially humanized Nanobodies) may in particular be characterized by the presence of one or more "hallmark residues" in one or more framework sequences. Further description of Nanobodies, including humanization and / or camelization of Nanobodies, as well as other modifications, parts or fragments, derivatives, or "nanobody fusions", multivalent constructs (including some non-limiting examples of linker sequences) and various modifications to extend the half-life of Nanobodies, and their preparation, can be found, for example, in WO 08 / 101985 and WO 08 / 142164.

[0078] Thus, within the meaning of the present invention, the term "immunoglobulin single variable domain" or "single variable domain" includes polypeptides derived from a source other than human, preferably camelid, preferably camelid heavy chain antibodies. They may be humanized as previously described. Furthermore, the term also includes polypeptides derived from a source other than camelid, e.g. mouse or human, that have been "camelized", e.g. as described in Davies and Riechmann 1994 (FEBS 339: 285), 1995 (Biotechonol. 13: 475) and 1996 (Prot. Eng. 9: 531) and Riechmann and Muyldermans 1999 (J. Immunol. Methods 231: 25).

[0079] The term "immunoglobulin single variable domain" encompasses immunoglobulin sequences of various origins, including mouse, rat, rabbit, donkey, human and camel immunoglobulin sequences. It also includes fully human, humanized or chimeric immunoglobulin sequences. For example, it includes camelid immunoglobulin sequences and humanized camelid immunoglobulin sequences, or camelidized immunoglobulin single variable domains, such as camelidized dAbs as described by Ward et al (see, for example, WO 94 / 04678 and Davies and Riechmann 1994, 1995 and 1996).

[0080] The invention may be used for the expression or production of any of the immunoglobulin single variable domains described herein. The invention may also be used for the expression or production of a polypeptide of the invention (i.e. a polypeptide comprising or substantially consisting of such an immunoglobulin single variable domain). In a particular embodiment, the invention may be used for the expression or production of an immunoglobulin single variable domain comprising two disulfide bridges. The invention may also be used for the expression or production of a polypeptide of the invention having two disulfide bridges (i.e. a polypeptide comprising or substantially consisting of such an immunoglobulin single variable domain). The invention may also be used for the expression or production of a polypeptide of the invention (i.e. a polypeptide comprising or substantially consisting of such an immunoglobulin single variable domain having two disulfide bridges).

[0081] All VHHs are known to contain at least one disulfide bridge between the cysteine ​​residue at position 22 and the cysteine ​​residue at position 92 (numbering according to Kabat, see patent application of Ablynx NV and Muyldermans and Lauwereys 1999, J. Mol. Recognit. 12: 131). While most VHHs only contain this single disulfide bridge, some VHHs are known to contain a total of two (or in exceptional cases three) disulfide bridges. For example, the class of VHHs (and nanobodies) referred to as "VHH-1 type", "VHH-1 class" or other (as further defined herein) generally has a second disulfide bridge between the cysteine ​​residue at position 50 in CDR2 and a cysteine ​​residue present in CDR3 (or in exceptional cases in CDR1 or CDR2). Also, some VHHs from camels or dromedaries often have a disulfide bridge between a cysteine ​​residue present in CDR1 (or at position 45 in FR2) and a cysteine ​​residue present in CDR3 (Vu et al. 1997, Mol. Immunol. 34: 1121; Muyldermans and Lauwereys 1999). Some VHHs from llamas sometimes have a disulfide bridge between a cysteine ​​residue present in CDR1 (e.g. at position 33) and a cysteine ​​residue present in CDR3 (Vu et al., 1997).

[0082] In one specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residues at positions 22 and 92, and further comprises a disulfide bridge formed between a cysteine ​​residue in one of the framework regions and a cysteine ​​residue in one of the CDR regions.

[0083] In another specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residues at positions 22 and 92, and further comprises a disulfide bridge formed between a cysteine ​​residue in one of the framework regions and a cysteine ​​residue in CDR3.

[0084] In another specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residues at positions 22 and 92, and further comprises a disulfide bridge formed between a cysteine ​​residue in framework 2 (FR2) and a cysteine ​​residue in CDR3.

[0085] In another specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residues at positions 22 and 92, and further comprises a disulfide bridge formed between the cysteine ​​residue at position 45 in framework 2 (FR2) and a cysteine ​​residue in CDR3 (as in some VHHs derived from camels and dromedaries).

[0086] In another specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residues at positions 22 and 92, and further comprises a disulfide bridge formed between a cysteine ​​residue in one CDR and a cysteine ​​residue in another CDR.

[0087] In another specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residues at positions 22 and 92 and further comprises a disulfide bridge formed between a cysteine ​​residue in CDR3 and a cysteine ​​residue in another CDR (in particular in CDR1, as in some VHHs from camel, dromedary and llama).

[0088] In another specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residues at positions 22 and 92, and further comprises a disulfide bridge formed between a cysteine ​​residue in CDR1 and a cysteine ​​residue in another CDR.

[0089] In another specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residues at positions 22 and 92, and further comprises a disulfide bridge formed between a cysteine ​​residue in CDR1 and a cysteine ​​residue in CDR1.

[0090] In another specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residues at positions 22 and 92, and further comprises a disulfide bridge formed between a cysteine ​​residue in CDR1 and a cysteine ​​residue in CDR3 (as in some VHHs derived from camel, dromedary and llama).

[0091] In another specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residues at positions 22 and 92, and further comprises a disulfide bridge formed between the cysteine ​​at position 33 and a cysteine ​​residue within CDR3 (as in some VHHs derived from camel, dromedary and llama).

[0092] In another specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residues at positions 22 and 92, and further comprises a disulfide bridge formed between a cysteine ​​residue in CDR2 and a cysteine ​​residue in another CDR.

[0093] In another specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residues at positions 22 and 92, and further comprises a disulfide bridge formed between a cysteine ​​residue in CDR2 and a cysteine ​​residue in CDR2.

[0094] In another specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residues at positions 22 and 92 and further comprises a disulfide bridge formed between a cysteine ​​residue in CDR2 and a cysteine ​​residue in CDR3 (as in some VHHs derived from llamas).

[0095] In another specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residue at position 22 and the cysteine ​​residue at position 92, and further comprises a disulfide bridge formed between the cysteine ​​residue at position 50 and a cysteine ​​residue within another CDR, e.g. CDR1, CDR2 or CDR3 (like VHHs and nanobodies of the VHH1 type).

[0096] In another specific, but non-limiting embodiment, the immunoglobulin single variable domain comprises a disulfide bridge between the cysteine ​​residue at position 22 and the cysteine ​​residue at position 92, and further comprises a disulfide bridge formed between the cysteine ​​residue at position 50 and a cysteine ​​residue in CDR3 (like VHHs and nanobodies of the VHH1 type).

[0097] In a preferred, but non-limiting embodiment, the immunoglobulin single variable domain can be a "VHH1-type immunoglobulin single variable domain". For example, an amino acid sequence such as an immunoglobulin single variable domain or polypeptide of the invention can be such that the VHH1-type immunoglobulin single variable domain or VHH1-type sequence has the VHH1 consensus sequence (SEQ ID NO: 46): [ka] A VHH1-type immunoglobulin single variable domain is said to be a "VHH1-type immunoglobulin single variable domain" or "VHH1-type sequence" if it has 85% identity (using standard settings, i.e., the blastp algorithm with the blosom62 scoring matrix) to and has obligatorily a cysteine ​​at position 50, i.e., Cys50 (using Kabat numbering). These VHH1-type immunoglobulin single variable domains generally have (or can form) a disulfide bridge between Cys50 and a cysteine ​​residue in CDR3 (or in exceptional cases in CDR1 or CDR2).

[0098] The amino acid sequence, such as an immunoglobulin single variable domain or polypeptide of the invention, may be such that the VHH2-type immunoglobulin single variable domain or VHH2-type sequence comprises the VHH2 consensus sequence (SEQ ID NO: 47): [ka] A VHH2-type immunoglobulin single variable domain is said to be a "VHH2-type sequence" if it has 85% identity to the VHH2-type immunoglobulin single variable domain (VHH2-type sequence) (using the blastp algorithm with standard settings, i.e., the blastom62 scoring matrix).

[0099] An amino acid sequence, such as an immunoglobulin single variable domain or polypeptide according to the invention, may be selected from the group consisting of a VHH3-type immunoglobulin single variable domain or a VHH3-type sequence, which comprises the VHH3 consensus sequence (SEQ ID NO: 48): [ka] A VHH3-type immunoglobulin single variable domain is said to be a "VHH3-type sequence" if it has 85% identity to the VHH3-type immunoglobulin single variable domain (VHH3-type sequence) (using the blastp algorithm with standard settings, i.e., the blastom62 scoring matrix).

[0100] It should be noted that although the present invention is particularly suitable for the expression of VHH1 (where the presence of two disulfide bridges is very common), the present invention can also be applied to the expression of VHH2 or VHH3 (which may or may not contain two disulfide bridges, which is less common).

[0101] For a general description and for some non-limiting examples of Nanobodies (and polypeptides comprising same) that are directed against c-Met and that can be expressed / produced using the methods described herein, see WO 2012 / 042026 and WO 2013 / 045707.

[0102] For a general description and for some non-limiting examples of Nanobodies (and polypeptides comprising same) directed against TNF and that can be expressed / produced using the methods described herein, see US Provisional Application US62 / 254,375 to Ablynx NV (see also PCT / EP2016 / 077595).

[0103] The inventors also anticipate that this teaching is particularly applicable to VHHs and nanobodies with two or more disulfide bridges, such as VHH-1, but also to other immunoglobulin single variable domains containing two or more disulfide bridges (e.g. (single) domain antibodies, dAbs, IgNAR domains from sharks, etc.).

[0104] Polypeptides of the Invention The immunoglobulin single variable domains prepared by the methods of the invention may form part of a protein or polypeptide (herein referred to as a "polypeptide of the invention") which may comprise or consist essentially of one or more (at least one) immunoglobulin single variable domains and may optionally further comprise one or more additional amino acid sequences (all optionally linked via one or more suitable linkers). The term "immunoglobulin single variable domain" may also encompass such polypeptides of the invention. One or more immunoglobulin single variable domains may be used as binding units in such proteins or polypeptides, which may optionally contain one or more further amino acids which may also serve as binding units, thereby providing monovalent, multivalent or multispecific polypeptides of the invention, respectively (for multivalent and multispecific polypeptides containing one or more VHH domains and their preparation see Conrath et al. 2001 (J. Biol. Chem. 276: 7346) and also for example WO 96 / 34103, WO 99 / 23221 and WO 2010 / 115998).

[0105] A polypeptide of the invention may comprise or consist essentially of one immunoglobulin single variable domain, as outlined above. Such polypeptides are also referred to herein as monovalent polypeptides.

[0106] The polypeptides of the invention may also encompass constructs comprising two or more antigen binding sites in the form of single variable domains as outlined above. For example, two (or more) immunoglobulin single variable domains with the same or different antigen specificities can be linked to form, for example, bivalent, trivalent or multivalent constructs. By combining immunoglobulin single variable domains with two or more specificities, bispecific, trispecific etc. constructs can be formed. For example, an immunoglobulin single variable domain according to the invention may comprise two or three immunoglobulin single variable domains directed against the same target, or one or two immunoglobulin single variable domains directed against target A and one immunoglobulin single variable domain directed against target B. All such constructs and modifications thereof that the skilled person can easily imagine are encompassed by the term polypeptide of the invention as used herein.

[0107] Additionally, the methods of the invention also allow for the preparation of fused immunoglobulin sequences that contain tags or other functional moieties, such as toxins, labels, radiochemicals, and the like.

[0108] In alternative embodiments, a polypeptide of the invention comprising or consisting essentially of one or more immunoglobulin single variable domains (or suitable fragments thereof) may further comprise one or more other groups, residues, moieties or binding units. Such further groups, residues, moieties, binding units or amino acid sequences may or may not provide an additional function to the immunoglobulin single variable domain (and / or to the polypeptide in which it is found) and may or may not modify the properties of the immunoglobulin single variable domain.

[0109] For example, such further groups, residues, moieties or binding units may be one or more additional amino acids, such that the compound, construct or polypeptide is a (fusion) protein or a (fusion) polypeptide. In a preferred but non-limiting aspect, said one or more other groups, residues, moieties or binding units are immunoglobulins. Even more preferably, said one or more other groups, residues, moieties or binding units are selected from the group consisting of a domain antibody, an amino acid suitable for use as a domain antibody, a single domain antibody, an amino acid suitable for use as a single domain antibody, a "dAb", an amino acid suitable for use as a dAb, or a nanobody.

[0110] Alternatively, such groups, residues, moieties or binding units may be, for example, chemical groups, residues, moieties which may or may not themselves be biologically and / or pharmacologically active. For example, and not by way of limitation, such groups may be linked to one or more immunoglobulin single variable domains to provide "derivatives" of the immunoglobulin single variable domains.

[0111] In a preferred, but non-limiting aspect, said additional residues may be effective to prevent or reduce binding of so-called "pre-existing antibodies" to the polypeptides of the invention. To this end, the polypeptides and constructs of the invention may contain a C-terminal extension (X)n, where n is 1-10, preferably 1-5, such as 1, 2, 3, 4, or 5 (preferably 1 or 2, e.g. 1); each X is an independently selected (preferably naturally occurring) amino acid residue, preferably selected from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I), as described in the following co-pending U.S. provisional applications, all entitled "Improved immunoglobulin variable domains": U.S. Patent No. 61 / 994,552, filed May 16, 2014; U.S. Patent No. 61 / 014,015, filed June 18, 2014; U.S. Patent No. 62 / 040,167, filed August 21, 2014; and U.S. Patent No. 62 / 047,560, filed September 8, 2014 (all to Ablynx). NV) and the international application WO 2015 / 173325, which is based on these provisional applications and was published on November 19, 2015.

[0112] Thus, in the method of the invention, said polypeptide may further comprise a C-terminal extension (X)n, where n is 1 to 5, such as 1, 2, 3, 4 or 5, and X is a naturally occurring amino acid, preferably not including any cysteine.

[0113] In a preferred embodiment, a polypeptide of the invention expressed in a method of the invention comprises or consists essentially of SEQ ID NO: 55. In a particular embodiment, such a polypeptide consists of SEQ ID NO:55.

[0114] In the above polypeptides, the one or more immunoglobulin single variable domains and the one or more groups, residues, moieties or binding units may be linked to each other directly and / or via one or more suitable linkers or spacers. For example, when the one or more groups, residues, moieties or binding units are amino acids, the linker may also be an amino acid, and the resulting polypeptide is thus a fusion protein or fusion polypeptide.

[0115] In one specific embodiment of the invention, polypeptides of the invention are prepared which have an extended half-life compared to the corresponding immunoglobulin single variable domain. For example, polypeptides of the invention comprising such half-life extending moieties include polypeptides in which an immunoglobulin single variable domain is suitably linked to one or more serum proteins or fragments thereof (e.g. (human) serum albumin or a suitable fragment thereof) or to one or more binding units capable of binding to a serum protein (e.g. domain antibodies, amino acids suitable for use as a domain antibody, single domain antibodies, amino acids suitable for use as a single domain antibody, "dAbs", amino acids suitable for use as a dAb, or serum albumin (e.g. human serum albumin), serum immunoglobulins (e.g. IgG) or or transferrin; polypeptides in which an immunoglobulin single variable domain is linked to an Fc portion (e.g. human Fc) or a suitable portion or fragment thereof; or polypeptides in which one or more immunoglobulin single variable domain(s) are suitably linked to one or more small proteins or peptides capable of binding to a serum protein (e.g., but not limited to, the proteins and peptides described in WO 91 / 01743, WO 01 / 45746, or WO 02 / 076489).

[0116] Generally, a polypeptide of the invention with an extended half-life preferably has a half-life that is at least 1.5 times, preferably at least 2 times, such as at least 5 times, for example at least 10 times, or more than 20 times, the half-life of the corresponding immunoglobulin single variable domain or polypeptide of the invention alone.

[0117] In a preferred, but non-limiting aspect, such a polypeptide of the invention has a serum half-life that is extended by at least 1 hour, preferably at least 2 hours, more preferably at least 6 hours, such as at least 12 hours, or even at least 24, 48, or 72 hours, compared to the corresponding immunoglobulin single variable domain or polypeptide of the invention alone.

[0118] In another preferred but non-limiting embodiment, such a polypeptide of the present invention exhibits a serum half-life in humans of at least about 12 hours, preferably at least 24 hours, more preferably at least 48 hours, and even more preferably at least 72 hours or more. For example, the polypeptide of the present invention may have a half-life of at least 5 days (e.g., about 5 to 10 days), preferably at least 9 days (e.g., about 9 to 14 days), more preferably at least about 10 days (e.g., about 10 to 15 days), or at least about 11 days (e.g., about 11 to 16 days), more preferably at least about 12 days (e.g., about 12 to 18 days or more), or 14 days or more (e.g., about 14 to 19 days).

[0119] The methods of the invention are particularly suitable for immunoglobulin single variable domains and / or polypeptides of the invention that are not readily expressible in Pichia, such as P. pastoris, or that give very low yields when expressed under expression conditions applicable for use in these hosts, such that expression of these immunoglobulin single variable domains or polypeptides of the invention in Pichia, such as P. pastoris, does not give sufficient amounts. Thus, the methods of the invention are particularly suitable for immunoglobulin single variable domains and / or polypeptides of the invention that give low yields when expressed in a Pichia host (e.g. P. pastoris) under standard Pichia expression conditions (as defined herein). "Low yield" as used herein means that the yield of immunoglobulin single variable domains and / or polypeptides of the invention obtained is 0.5 g / L or less, such as 0.4 g / L or less, 0.3 g / L or less, 0.2 g / L or less, 0.1 g / L or less, 0.05 g / L or less, 0.01 g / L or less, or even lower [expressed as g (grams) of immunoglobulin single variable domains or polypeptides of the invention per L (liter) of culture medium].

[0120] The methods of the invention are also particularly suitable for immunoglobulin single variable domains and polypeptides of the invention in which the yield obtained when expressed in a Pichia host (e.g. P. pastoris) under standard Pichia expression conditions (as defined herein) correlates inversely (as defined herein) with the copy number of the nucleic acid encoding said immunoglobulin single variable domain and / or polypeptide. By "inversely correlated" we mean that the yield of said immunoglobulin single variable domain and / or polypeptide obtained is higher when said immunoglobulin single variable domain and / or polypeptide is expressed (under standard Pichia expression conditions as defined herein) in a Pichia host having one copy of a nucleic acid encoding said immunoglobulin single variable domain and / or polypeptide than the yield of said immunoglobulin single variable domain and / or polypeptide obtained when said immunoglobulin single variable domain and / or polypeptide is expressed (under standard Pichia expression conditions as defined herein) in a Pichia host having more than one copy of a nucleic acid encoding said immunoglobulin single variable domain and / or polypeptide.

[0121] Preferred polypeptides for use in the methods of the present invention include SEQ ID NOs: 49 to 54. These sequences also form separate aspects of the present invention. Thus, the present invention also relates to polypeptides having SEQ ID NOs: 49, 50, 51, 52, 53, 54, 55, or 56.

[0122] Other particularly preferred polypeptides for use in the methods of the invention comprise or essentially consist of an immunoglobulin single variable domain consisting essentially of four framework regions (FR1 to FR4, respectively) and three complementarity determining regions (CDR1 to CDR3, respectively), where CDR1 is SEQ ID NO: 58, CDR2 is SEQ ID NO: 60 and CDR3 is SEQ ID NO: 62, e.g. an immunoglobulin single variable domain having the amino acid sequence of SEQ ID NO: 55 or 56.

[0123] Accessory proteins The term "auxiliary protein" as used herein refers to a protein that assists other molecular structures and / or proteins in carrying out their biological functions, but does not itself appear in the structure of these other molecular structures and / or proteins when these other molecular structures and / or proteins carry out their normal biological functions. An auxiliary protein may, for example, modify the biophysical, pharmacological, and / or expression properties of the other molecular structures and / or proteins. Without being limited thereto, auxiliary proteins may stabilize other molecular structures and / or proteins (e.g., through the formation of a complex), they may regulate the activity of other molecular structures and / or proteins, they may increase the (surface) expression of other molecular structures and / or proteins, and / or they may assist in folding and / or assembly.

[0124] The auxiliary protein whose expression is enhanced in the method of the invention is a functional HAC1 protein. The HAC1 protein may originate from any species, but is preferably of yeast origin, most preferably from Saccharomyces, such as yeast from the genera Saccharomyces, Komagataella or Pichia (Hansenula), such as Saccharomyces cerevisiae or Pichia pastoris. In a specific embodiment, the functional HAC1 protein is a "HAC1 splice form" or "HAC1 splice form protein" (both terms are used interchangeably herein). The HAC1 splice form is a HAC1 protein obtained after a splicing event (removal of the intron) on the HAC1 mRNA as described in Guerfal et al. 2010 (Microbial Cell Factories 9: 49). In a more specific embodiment, the HAC1 splice form protein is of Pichia origin. In a preferred embodiment, the HAC1 splice form protein has the sequence as set forth in Guerfal et al. 2010 (Microbial Cell Factories 9: 49; SEQ ID NO: 14).

[0125] In the methods of the invention, in addition to the HAC1 protein, the expression of one or more additional auxiliary proteins, optionally selected from protein disulfide isomerase (PDI1; EC 5.3.4.1), Kar2p and conserved ribosomal protein P0 (RPP0), is enhanced. These auxiliary proteins may originate from any species, as long as their enhanced expression in the Pichia host provides an increased yield of the immunoglobulin single variable domains and / or polypeptides of the invention. In a preferred embodiment, the auxiliary proteins originate from a fungus, such as a yeast; preferably a yeast from the Saccharomyces genus, such as a yeast from the genus Saccharomyces, Komagataella genus, or Pichia (Hansenula) genus, such as Saccharomyces cerevisiae or Pichia pastoris.

[0126] In a preferred embodiment, the auxiliary protein is: -HAC1 splice form of P. pastoris [ka] and optionally one or more of the following: - Protein disulfide isomerase (PDI1) of P. pastoris: [ka] -P. Pastoris' Kar2p: [ka] and - 60S acidic ribosomal protein P0 (RPP0) of P. pastoris: [ka] is selected from.

[0127] Methods of the Invention The present invention relates to a method for expressing and / or producing an immunoglobulin single variable domain and / or a polypeptide comprising same in a Pichia host, in which the expression of the HAC1 splice form protein in the Pichia host is enhanced. The method of the present invention comprises the steps of: a) expressing in a Pichia host a nucleic acid encoding an immunoglobulin single variable domain and / or a polypeptide of the invention; and b) enhancing expression of nucleic acid(s) encoding a HAC1 splice form protein in said Pichia host; followed by; c) isolating and / or purifying the immunoglobulin single variable domains and / or polypeptides of the invention thus obtained.

[0128] Thus, the method of the present invention comprises: a) culturing the Pichia host under conditions such that the Pichia host grows; b) maintaining the Pichia host under conditions such that the Pichia host expresses and / or produces the immunoglobulin single variable domains and / or polypeptides of the invention; and c) enhancing expression of a nucleic acid encoding a HAC1 splice form protein in said Pichia host; Optionally followed by: d) isolating and / or purifying the immunoglobulin single variable domains and / or polypeptides of the invention thus obtained from the culture medium. Includes.

[0129] To produce / obtain expression of the immunoglobulin single variable domains and / or polypeptides of the invention, the transformed Pichia host may generally be kept, maintained and / or cultured under conditions such that the (desired) immunoglobulin single variable domains and / or polypeptides of the invention are expressed / produced. Suitable conditions will be clear to the skilled artisan and will usually depend on the Pichia host strain used, as well as on the regulatory sequences controlling the expression of the (relevant) nucleotide sequences of the invention.

[0130] In general, appropriate conditions may include the use of an appropriate medium, the presence of a suitable food source and / or suitable nutrients, the use of an appropriate temperature, and optionally the presence of a suitable inducer or compound (e.g., when the nucleotide sequence(s) of the invention are under the control of an inducible promoter); all of which may be selected by one of skill in the art. Again, under such conditions, the immunoglobulin single variable domains and / or polypeptides of the invention may be constitutively expressed, transiently expressed, or expressed only when appropriately induced.

[0131] Culture conditions for recombinant production of heterologous proteins in Pichia are described, for example, in Higgins and Cregg 1998 (Eds. Methods in Molecular Biology, Pichia protocols, Volume 103, 2 nd Ed., Humana Press) and by Invitrogen™ (Invitrogen™ Pichia Expression Kit; for expression of recombinant proteins in Pichia pastoris; Cat. No. K1710-01). The production of immunoglobulin single variable domains in P. pastoris is extensively described in WO 94 / 25591, WO 2010 / 125187, WO 2012 / 056000 and WO 2012 / 152823. Explicit reference is made to the contents of these documents with respect to general culture techniques and methods, including suitable media and conditions. The contents of these documents are incorporated by reference. The present invention also relates to specific conditions described in the art, e.g. the general culture methods described in WO 94 / 25591, Gasser et al. 2006 (Biotechnol. Bioeng. 94: 535); Gasser et al. 2007 (Appl. Environ. Microbiol. 73: 6499), or Damasceno et al. 2007 (Microbiol. Biotechnol. 74: 381).

[0132] Pichia, particularly P. pastoris, is typically cultured in fed-batch fermentation at 30°C using glycerol as the carbon source. Such media generally contain a buffer, glycerol, trace elements and ammonium hydroxide. Examples of buffers include (but are not limited to) H3PO4, CaSO4·2H2O, K2SO4, MgSO4·7H2O, and KOH. A typical growth medium (e.g., basal salts medium) consists (per liter) of 26.7 mL of 85% H3PO4, 0.93 g CaSO4·2H2O, 18.2 g K2SO4, 14.9 g MgSO4·7H2O, 4.13 g KOH, 40 g glycerol, 2 mL of trace elements (6 g / L copper sulfate·5H2O; 0.8 g / L potassium iodide; 3 g / L manganese sulfate·H2O; 0.2 g / L sodium molybdate·2H2O; 0.2 g / L boric acid; 0.5 g / L copper sulfate; 20 g / L zinc chloride; 65 g / L ferrous sulfate·7H2O; 0.2 g / L biotin, and 5 mL of concentrated sulfuric acid). Ammonium hydroxide (NH4OH) is used for pH adjustment (e.g., pH 5) and as a nitrogen source. During the fed-batch period, glycerol (e.g., 50% v / v) is fed over several hours at a feed rate of, e.g., 15 mL / L / h. The AOX1 promoter is used to drive expression of the gene of interest encoding the desired immunoglobulin single variable domain and / or polypeptide of the invention. Expression of the immunoglobulin single variable domain and / or polypeptide of the invention is carried out at 30° C. with a methanol feed rate of 4-10 mL / L / h (e.g., 4 mL / L / h). These conditions are also referred to herein as "standard Pichia expression conditions."

[0133] Expression of auxiliary proteins can be enhanced by commonly known means, including the use of appropriate control sequences, such as strong promoters, and / or increasing the amount of genes, for example by increasing the copy number of the respective genes. The copy number can be increased, for example, by introducing a suitable genetic construct (plasmid or vector) for expression of the auxiliary protein. The additional presence of a plasmid or vector will increase the total copy number. Furthermore, genetic constructs may be used that can amplify independently of the Pichia host genome and are present in multiple copies within the Pichia host. For example, a multicopy plasmid or vector may be present in the Pichia host cell, with a copy number of 5 to 50.

[0134] In addition to the transformation of the Pichia host by a plasmid or vector, the transformation of the Pichia host chromosome is also encompassed by the present invention. A strong (inducible) promoter (instead of the native promoter of the native auxiliary protein) may be introduced into the host chromosome; or another copy of the auxiliary protein gene sequence under the control of another (strong) promoter may be introduced into the chromosome. The skilled artisan is aware of many possibilities to enhance the expression of the auxiliary protein, all of which are encompassed by the present invention.

[0135] The accessory protein(s) and the immunoglobulin single variable domains and / or polypeptides of the invention may be expressed from the same or different nucleic acids. Co-expression of two or more proteins may be achieved by expression of two or more proteins on the same genetic construct (integrated into a plasmid or vector or into the host's chromosome); or by expression of two or more proteins on different genetic constructs (integrated into a plasmid or vector or into the host's chromosome).

[0136] When expressed on the same genetic construct, the nucleic acids encoding said two or more proteins are preferably located next to each other. The transcription of the nucleic acids encoding said two or more proteins may be controlled by one promoter (located in front of both genes); or each nucleic acid encoding one of said two or more proteins may be controlled by a separate promoter, which may be the same or different promoters.

[0137] When expressed from different genetic constructs, the transcription of the nucleic acid encoding the polypeptide of the invention and the transcription of the nucleic acid encoding one or more auxiliary protein(s) may be controlled by two separate promoters, which may be the same or different.

[0138] The promoter may be a constitutive or an inducible promoter. In a preferred embodiment, the promoter is an inducible promoter.

[0139] The number of auxiliary proteins whose expression is enhanced in the methods of the invention may be 1 (HAC1 splice form protein) or may be more than 1, for example 2, 3, 4, 5 or more. In a preferred embodiment, the number of auxiliary proteins whose expression is enhanced in the methods of the invention is 1 (HAC1 splice form protein).

[0140] In another preferred embodiment, the number of auxiliary proteins whose expression is enhanced in the method of the present invention is two, three, four, or even more. In this preferred embodiment, the expression of HAC1 splice form protein is enhanced and further the expression of one or more additional auxiliary proteins is enhanced. The additional auxiliary proteins can be any auxiliary proteins available and / or known in the art. Preferably, the additional auxiliary proteins are selected from any of PDI1, Kar2p, and RPP0.

[0141] Thus, the method of the invention also encompasses the expression and / or production of an immunoglobulin single variable domain and / or a polypeptide comprising same in a Pichia host, whereby expression of the HAC1 splice form protein and one or more additional accessory proteins selected from PDI1, Kar2p and RPP0 is enhanced. a) expressing in a Pichia host a nucleotide sequence encoding an immunoglobulin single variable domain and / or a polypeptide of the invention; b) enhancing expression of a nucleic acid encoding a HAC1 splice form protein and one, two, three (or more) nucleic acids encoding accessory proteins selected from PDI1, Kar2p and RPP0 in said Pichia host; Optionally followed by: c) isolating and / or purifying the immunoglobulin single variable domains and / or polypeptides of the invention thus obtained. The present invention also relates to a method comprising the steps of:

[0142] In a specific embodiment, the method of the invention comprises: a) culturing the Pichia host under conditions such that the Pichia host grows; b) maintaining the Pichia host under conditions such that the Pichia host expresses and / or produces the immunoglobulin single variable domains and / or polypeptides of the invention; and c) enhancing expression of a nucleic acid encoding a HAC1 splice form protein and one, two, three (or more) nucleic acids encoding accessory proteins selected from PDI1, Kar2p and RPP0 in said Pichia host; Optionally followed by: d) isolating and / or purifying the immunoglobulin single variable domains and / or polypeptides of the invention thus obtained from the culture medium. Includes.

[0143] Thus, in this particular embodiment of the method of the present invention, combinations of the following auxiliary protein(s) may be enhanced: -PDI1 and HAC1 splice forms; -Kar2p and HAC1 splice forms; -RPP0 and HAC1 splice types; -PDI1, Kar2p and HAC1 splice forms; -PDI1, RPP0 and HAC1 splice forms; -Kar2p, RPP0 and HAC1 splice forms; and -PDI1, Kar2p, RPP0 and HAC1 splice forms.

[0144] When the number of auxiliary proteins is two or more, the auxiliary proteins can be expressed by the action of the same genetic construct, such as the expression of two or more auxiliary proteins on one plasmid or vector; or by the expression of two or more auxiliary proteins on different plasmids or vectors. In addition to the transformation of the Pichia host with a plasmid or vector, the transformation of the chromosome of the Pichia host is also encompassed by the present invention. A strong (inducible) promoter (instead of the native promoter of the native auxiliary protein) can be introduced into the chromosome of the Pichia host; another copy of the auxiliary protein gene sequence under the control of another (strong) promoter can be introduced into the chromosome. When expressed on the same genetic construct, the two or more auxiliary proteins can be controlled by the same promoter or by different promoters. When expressed from different genetic constructs, the two or more auxiliary proteins can be controlled by two separate promoters, which can be the same or different. The promoters can be constitutive or inducible promoters.

[0145] By using the above method, the inventors were able to increase the unexpectedly low yields sometimes observed for immunoglobulin single variable domains and / or polypeptides comprising same, which have been observed in particular for immunoglobulin single variable domains (and / or polypeptides comprising same) that comprise two disulfide bridges, for immunoglobulin single variable domains (and / or polypeptides comprising same) that are VHH1-type immunoglobulin single variable domains, and / or for immunoglobulin single variable domains (and / or polypeptides comprising same) where the yield obtained when expressed in a Pichia host under standard Pichia expression conditions correlates inversely with the copy number of the nucleic acid encoding said immunoglobulin single variable domain (and / or polypeptide comprising same).

[0146] Thus, the present invention also provides a method for increasing the (expression and / or production) yield of an immunoglobulin single variable domain and / or a polypeptide comprising same, comprising the steps of: a) expressing in a Pichia host a nucleic acid encoding an immunoglobulin single variable domain and / or a polypeptide of the invention; and b) enhancing expression of a nucleic acid encoding a HAC1 splice form protein in said Pichia host; Optionally followed by: c) isolating and / or purifying the immunoglobulin single variable domains and / or polypeptides of the invention thus obtained. Includes.

[0147] Thus, a method for increasing the (expression and / or production) yield of an immunoglobulin single variable domain and / or polypeptide comprises: a) culturing the Pichia host under conditions such that the Pichia host grows; b) maintaining the Pichia host under conditions such that the Pichia host expresses and / or produces the immunoglobulin single variable domains and / or polypeptides of the invention; and c) enhancing expression of a nucleic acid encoding a HAC1 splice form protein in said Pichia host; Optionally followed by: d) isolating and / or purifying the immunoglobulin single variable domains and / or polypeptides of the invention thus obtained from the culture medium. Includes.

[0148] In a preferred embodiment, the method of the invention provides a yield of immunoglobulin single variable domains and / or polypeptides of the invention that is at least twice (preferably 3 or 4 or more times, more preferably 5, 7.5, 10, 15, 20, 25, 30, 40, 50 or even more times) the yield of said immunoglobulin single variable domains and / or polypeptides of the invention obtained by a method in which expression of the HAC1 splice form protein is not enhanced.

[0149] Thus, in a preferred aspect, the present invention also provides a method for increasing the yield (expression and / or production) of an immunoglobulin single variable domain and / or a polypeptide comprising same, comprising the steps of: a) expressing in a Pichia host a nucleic acid encoding an immunoglobulin single variable domain and / or a polypeptide of the invention; and b) enhancing expression of a nucleic acid encoding a HAC1 splice form protein in said Pichia host; Optionally followed by: c) isolating and / or purifying the immunoglobulin single variable domains and / or polypeptides of the invention thus obtained. which method provides a yield of immunoglobulin single variable domains and / or polypeptides of the invention that is at least 2-fold (preferably 3-fold or 4-fold or more, more preferably 5-fold, 7.5-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold or even more) than the yield of immunoglobulin single variable domains and / or polypeptides of the invention obtained with a method in which expression of the HAC1 splice form protein is not enhanced.

[0150] Thus, a method for increasing the (expression and / or production) yield of an immunoglobulin single variable domain and / or polypeptide comprises: a) culturing the Pichia host under conditions such that the Pichia host grows; b) maintaining the Pichia host under conditions such that the Pichia host expresses and / or produces the immunoglobulin single variable domains and / or polypeptides of the invention; and c) enhancing expression of a nucleic acid encoding a HAC1 splice form protein in said Pichia host; Optionally followed by: d) isolating and / or purifying the immunoglobulin single variable domains and / or polypeptides of the invention thus obtained from the culture medium. which method provides a yield of immunoglobulin single variable domains and / or polypeptides of the invention that is at least 2-fold (preferably 3-fold or 4-fold or more, more preferably 5-fold, 7.5-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold or even more) than the yield of immunoglobulin single variable domains and / or polypeptides of the invention obtained with a method in which expression of the HAC1 splice form protein is not enhanced.

[0151] In another preferred embodiment, the method of the invention provides a yield of immunoglobulin single variable domains and / or polypeptides of the invention of 1 g / L or more, more preferably 1.5 g / L or more, 2 g / L or more, or even 2.5 g / L or more.

[0152] Therefore, in another preferred aspect, the present invention also provides a method for increasing the (expression and / or production) yield of an immunoglobulin single variable domain and / or a polypeptide comprising same, comprising the steps of: a) expressing in a Pichia host a nucleic acid encoding an immunoglobulin single variable domain and / or a polypeptide of the invention; and b) enhancing expression of a nucleic acid encoding a HAC1 splice form protein in said Pichia host; Optionally followed by: c) isolating and / or purifying the immunoglobulin single variable domains and / or polypeptides of the invention thus obtained. wherein the method provides a yield of immunoglobulin single variable domains and / or polypeptides of the invention of 1 g / L or more, more preferably 1.5 g / L or more, 2 g / L or more, or even 2.5 g / L or more.

[0153] Thus, a method for increasing the (expression and / or production) yield of an immunoglobulin single variable domain and / or polypeptide comprises: a) culturing the Pichia host under conditions such that the Pichia host grows; b) maintaining the Pichia host under conditions such that the Pichia host expresses and / or produces the immunoglobulin single variable domains and / or polypeptides of the invention; and c) enhancing expression of a nucleic acid encoding a HAC1 splice form protein in said Pichia host; Optionally followed by: d) isolating and / or purifying the immunoglobulin single variable domains and / or polypeptides of the invention thus obtained from the culture medium. wherein the method provides a yield of immunoglobulin single variable domains and / or polypeptides of the invention of 1 g / L or more, more preferably 1.5 g / L or more, 2 g / L or more, or even 2.5 g / L or more.

[0154] The immunoglobulin single variable domains and / or polypeptides of the invention are produced extracellularly and isolated from the medium in which the Pichia host cells are cultured.

[0155] Typically, but not necessarily, the immunoglobulin single variable domains and / or polypeptides of the invention will have at least one transport signal that directs the immunoglobulin single variable domains and / or polypeptides of the invention to the periplasm. In the present invention, the Pichia host can be removed from the culture medium by routine means. For example, the Pichia host can be removed by centrifugation or filtration. The solution obtained by removal of the Pichia host from the culture medium is also referred to as culture supernatant or clarified culture supernatant.

[0156] It will be clear to the skilled artisan that the immunoglobulin single variable domains and / or polypeptides of the invention may also be (first) produced in an immature form (as described above) and then subjected to post-translational modifications depending on the Pichia host cell used. The immunoglobulin single variable domains and / or polypeptides of the invention may also be glycosylated, again depending on the Pichia host cell used.

[0157] The immunoglobulin single variable domains and / or polypeptides of the invention can then be isolated from the Pichia host and / or from the medium in which said Pichia host was cultured by standard methods. Standard methods include, but are not limited to, chromatographic methods such as size-exclusion chromatography, hydrophobic chromatography, ion-exchange chromatography and affinity chromatography. These methods can be performed alone or in combination with other purification methods, such as differential precipitation techniques, gel electrophoresis, affinity techniques (e.g. using specific, cleavable amino acid sequences fused to the immunoglobulin single variable domains and / or polypeptides of the invention) and / or immunopreparation techniques (i.e. using antibodies against the immunoglobulin single variable domains and / or polypeptides of the invention to be isolated). The skilled person can devise suitable combinations of purification methods for immunoglobulin single variable domains on the basis of his general knowledge. For specific examples, reference is made to the techniques cited herein.

[0158] Immunoglobulin single variable domains and / or polypeptides comprising same can be purified from culture supernatants by a combination of Protein A affinity chromatography, ion exchange chromatography and size exclusion chromatography. Reference to any "purification step" includes, but is not limited to, these specific methods. More specifically, immunoglobulin single variable domains and / or polypeptides comprising same can be purified from culture supernatants using a process in which the clarified supernatant (obtained by centrifugation) is captured on a Protein A resin; followed by a SOURCE15S (GE Healthcare) cation exchange chromatography step and a Superdex 75 (GE Healthcare) size exclusion chromatography step.

[0159] Following removal of the Pichia host, the immunoglobulin single variable domains and / or polypeptides of the invention may be present in a wide variety of suitable buffers, including but not limited to PBS, Tris-HCl, histidine or phosphate buffers, and may be present in saline.

[0160] Generally, for pharmaceutical use, the immunoglobulin single variable domains and / or polypeptides of the invention may be formulated as pharmaceutical preparations or compositions comprising at least one immunoglobulin single variable domain and / or polypeptide of the invention, at least one pharma- ceutically acceptable carrier, diluent or excipient and / or adjuvant, and optionally one or more further pharma- ceutically active polypeptides and / or compounds. By way of non-limiting examples, such formulations may be in a form suitable for oral administration, parenteral administration (e.g., by intravenous, intramuscular or subcutaneous injection, or intravenous infusion), topical administration, by inhalation, by skin patch, by implant, by suppository, etc. Such suitable administration forms (which may be in solid, semi-solid or liquid form, depending on the method of administration) as well as the methods and carriers used for their preparation will be apparent to the skilled artisan.

[0161] Nucleic acids and gene constructs of the invention The present invention also relates to nucleic acids encoding the immunoglobulin single variable domains and / or polypeptides and HAC1 splice forms of the invention, which are also referred to herein as "nucleic acid(s) of the invention".

[0162] The nucleic acid of the invention may be in the form of, present in and / or part of a genetic construct, as will be clear to the skilled person. Such a genetic construct generally comprises at least one nucleic acid of the invention, optionally linked to one or more sequences of a genetic construct known per se, such as one or more suitable control sequences (such as suitable promoter(s), enhancer(s), terminator(s), etc.) and further sequences of the genetic construct mentioned herein. Such a genetic construct comprising at least one nucleic acid of the invention is also referred to herein as "genetic construct(s) of the invention". Thus, the genetic construct of the invention at least codes for the immunoglobulin single variable domain and / or polypeptide of the invention and the HAC1 splice form.

[0163] The number of accessory proteins encoded by the nucleic acid(s) and genetic construct(s) of the invention may be one (i.e., a HAC1 splice form protein) or may be more than one, for example, two, three, four, five or more. In a preferred embodiment, the number of accessory proteins encoded by the nucleic acid(s) and genetic construct(s) of the invention is one (i.e., a HAC1 splice form protein). In another preferred embodiment, the number of accessory proteins encoded by the nucleic acid(s) and genetic construct(s) of the invention is two or more.

[0164] Thus, the present invention also encompasses nucleic acid or genetic constructs encoding the immunoglobulin single variable domains and / or polypeptides of the invention and two or more accessory proteins, including the HAC1 splice form proteins.

[0165] As discussed above, the immunoglobulin single variable domains and / or polypeptides of the invention and the accessory protein(s) may be co-expressed from one single nucleic acid and / or genetic construct; or alternatively, from different (separate) nucleic acids and / or genetic constructs (possibly including expression from the host chromosome). All such nucleic acids and / or genetic constructs (either as one construct or as separate constructs) encoding the immunoglobulin single variable domains and / or polypeptides of the invention and / or encoding the accessory protein(s) are encompassed by the terms "nucleic acid(s) of the invention" and "genetic construct(s) of the invention".

[0166] The nucleic acid of the invention may be in the form of single-stranded or double-stranded DNA or RNA, preferably in the form of double-stranded DNA. For example, the nucleic acid of the invention may be genomic DNA, cDNA, or synthetic DNA, such as DNA with a codon usage specifically adapted for expression in a Pichia host cell.

[0167] According to one embodiment of the invention, the nucleic acid of the invention is in a substantially isolated form as defined herein. The nucleic acid of the invention may also be in the form of, present within and / or be part of a vector, such as a plasmid, cosmid or YAC, again in a substantially isolated form.

[0168] The nucleic acids of the invention can be prepared or obtained in a manner known per se, based on information about the immunoglobulin single variable domains and / or polypeptides to be expressed and the auxiliary protein(s) used for co-expression. As will be clear to the skilled person, in order to prepare the nucleic acids of the invention, several nucleotide sequences may be linked to one another in a suitable manner, for example at least one nucleotide sequence encoding an immunoglobulin single variable domain and / or polypeptide of the invention with at least one nucleotide sequence encoding an auxiliary protein.

[0169] Techniques for generating the nucleic acids of the invention are clear to those skilled in the art and include, for example, but are not limited to, automated DNA synthesis, site-directed mutagenesis, combining two or more natural and / or synthetic sequences (or two or more portions thereof), introducing mutations that result in the expression of truncated expression products, introducing one or more restriction enzyme sites (e.g., to create cassettes and / or regions that can be easily digested and / or ligated using appropriate restriction enzymes), and / or introducing mutations using a PCR reaction using one or more "mismatched" primers. These and other techniques are clear to those skilled in the art and again reference is made to standard handbooks, such as Sambrook et al. and Ausubel et al., as described herein and in the Examples below.

[0170] The genetic construct of the present invention may be DNA or RNA, preferably double-stranded DNA. The genetic construct of the present invention may also be in a form suitable for transformation of a Pichia host, for integration into the genomic DNA of a Pichia host cell, or for independent replication, maintenance and / or inheritance in a Pichia host. For example, the genetic construct of the present invention may be in the form of a vector, such as a plasmid, a YAC, a viral vector, or a transposon. In particular, the vector may be an expression vector, i.e. a vector capable of conferring expression in a Pichia host.

[0171] In a preferred, but non-limiting embodiment, the genetic construct of the present invention comprises: a) at least one nucleic acid of the invention operably linked to: b) one or more control sequences, such as a promoter and, optionally, a suitable terminator; and possibly also c) one or more further sequences of the genetic construct, which are known per se and the terms "control sequence", "promoter", "terminator" and "operably connected" have their usual meaning in the art (as further described herein); said "further sequences" present in the genetic construct may be, for example, 3'- or 5'-UTR sequences, leader sequences, selection markers, expression markers / reporter genes and / or sequences which may facilitate or increase (the efficiency of) transformation or integration. These and other suitable sequences for such genetic constructs will be clear to the skilled person and depend, for example, on the type of construct used, the Pichia host strain, the manner in which the nucleotide sequence of the invention of interest is intended to be expressed (for example via constitutive, transient or inducible expression) and / or the transformation technique intended to be used. For example, control sequences, promoters and terminators known per se for the expression and production of antibodies and antibody fragments (including but not limited to (single) domain antibodies and ScFv fragments) may be used in a substantially similar manner.

[0172] Preferably, in a genetic construct of the invention, said at least one nucleic acid of the invention and said control sequence, and optionally said one or more further sequences, are "operably linked" to each other, by which it is generally meant that they are in a functional relationship with each other. For example, a promoter is deemed to be "operably linked" to a coding sequence if said promoter is capable of initiating or otherwise controlling / regulating the transcription and / or expression of said coding sequence (which coding sequence is to be understood as being "under the control" of said promoter). Generally, when two nucleotide sequences are operably linked, they are in the same orientation and usually in the same reading frame. They are also usually substantially contiguous, although this is also not required. In one aspect of the invention, a nucleotide sequence encoding an immunoglobulin single variable domain and / or polypeptide of the invention is operably linked to a nucleotide sequence encoding an auxiliary protein(s). They may be under the control of the same promoter or they may each be under the control of separate (same or different) promoters.

[0173] Methods for designing, making or obtaining nucleic acid sequences for expression, constructing a suitable vector, inserting a nucleic acid sequence into said vector, selecting a suitable Pichia host strain, introducing said vector into said Pichia host strain, causing or enabling expression of a polypeptide or protein, isolating nucleic acids from said Pichia host strain, or identifying nucleic acid sequences and corresponding protein sequences are standard methods well known to anyone of ordinary skill in the art (Sambrook et al. 1989). A person skilled in the art can also devise, based on his general knowledge, suitable genetic constructs for expressing the immunoglobulin single variable domains and / or polypeptides of the invention in a Pichia host. The present invention also refers to genetic constructs described in the art, for example plasmids, promoters and leader sequences described in WO 94 / 25591, Cereghino and Cregg 2000 (Curr. Opinion Biotechnol. 10: 422), Gasser et al. 2006 (Biotechnol. Bioeng. 94: 535), Gasser et al. 2007 (Appl. Environ. Microbiol. 73: 6499) or Damasceno et al. 2007 (Microbiol. Biotechnol. 74: 381).

[0174] Preferably, the control and further sequences of the genetic construct of the present invention are such that they are capable of conferring their intended biological function in the Pichia host.

[0175] For example, a promoter, enhancer, or terminator should be "operable" in a Pichia host, by which is meant that (for example) the promoter should be capable of initiating or otherwise controlling / regulating the transcription and / or expression of a nucleotide sequence, e.g., a coding sequence (as defined herein), to which it is operably linked.

[0176] Some preferred, but non-limiting examples of suitable promoters, terminators, and additional sequences include those that can be used for expression in Pichia hosts; in particular, those described herein and / or used in the Examples below.

[0177] Some particularly preferred promoters include promoters known per se for expression in Pichia hosts; in particular those described herein and / or used in the Examples. The specific sequence of the promoter determines the strength of the promoter (a "strong promoter" results in a high transcription initiation rate). When expression of a nucleic acid encoding an auxiliary protein is said to be controlled by a "strong promoter", it means that expression of the nucleic acid encoding the auxiliary protein is controlled by a promoter that results in a higher transcription initiation rate than the native promoter that controls transcription initiation of the native auxiliary protein. In addition to sequences that "enhance" transcription, promoters may contain additional sequences known as operators that control the strength of the promoter. For example, promoters may contain binding sites for proteins that attract or interfere with the binding of RNA to the promoter. The presence or absence of this protein will affect the strength of the promoter. Such promoters are known as regulated promoters.

[0178] The P. pastoris alcohol oxidase I (AOX1) promoter is one of the strongest and most regulated promoters known. Conversely, the second P. pastoris alcohol oxidase (AOX2) is controlled by a much weaker promoter. The P. pastoris glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter confers constitutively high levels of expression on glucose, glycerol, and methanol media (Waterham et al. 1997, Gene 186: 37). The P. pastoris formylaldehyde dehydrogenase (FLD1) promoter can be induced by either methanol or methylamine, with expression levels comparable to those obtained with the AOX1 promoter in methanol (Shen et al. 1998, Gene 216: 93). The peroxin 8 (PEX8) promoter confers low expression on glucose and is moderately induced (approximately 10-fold) when cells are switched to methanol (Johnson et al. 1999, Genetics 151: 1379).

[0179] Strong promoters in H. polymorpha include sequences derived from the methanol oxidase gene (MOX), formate dehydrogenase gene (FMD), and dihydroxyacetone synthase gene (DHAS) (Song et al. 2006, Biotechnol. Lett. 25: 1999). In H. polymorpha, the glyceraldehyde-3-phosphate dehydrogenase (GAP1) promoter (Sohn et al. 1999, Appl. Microbiol. Biotechnol. 51: 800) and the PMA1 promoter (Cox et al. 2000, Yeast 16: 1191) are constitutive sequences. The PMA1 promoter competes with the MOX promoter for high expression levels.

[0180] The alcohol oxidase (AUG1) promoters of Pichia methanolica, P(MOD1) and P(MOD2), are strongly and tightly regulated by methanol (P(MOD1) and P(MOD2)) and glycerol (P(MOD1) only) (Nakagawa et al. 2006, Yeast 23: 15).

[0181] Strong promoters from Candida boidinii include the alcohol oxidase (AOD1) promoter and the dihydroxyacetone synthase (DAS1) promoter (Yurimoto et al. 2000, Biochim. Biophys. Acta 1493: 56). Both the DAS1 promoter and the formate dehydrogenase (FMD) promoter are available in Candida boidinii (Sakai et al. 1995, Appl. Microbiol. Biotechnol. 42: 860; 1996, Biochim. Biophys. Acta 1308: 81) and Hansenula polymorpha (Hollenberg and Gellissen 1997, Curr. Opin. Biotechnol. 8: 554).

[0182] The selection marker should be such that it makes it possible to distinguish Pichia host cells that have been (successfully) transformed with a nucleic acid of the invention, i.e. under appropriate selection conditions, from Pichia host cells that have not been (successfully) transformed. Some preferred, but non-limiting examples of such markers are genes that confer resistance to antibiotics (such as zeocin, blasticidin, geneticin (G418), phleomycin, kanamycin, or ampicillin), genes that confer resistance to temperature, or genes that allow the Pichia host to be maintained in the absence of certain factors, compounds and / or (food) components in the medium that are essential for the survival of untransformed cells.

[0183] The leader sequence should be such that in the Pichia host it allows the desired post-translational modification and / or secretion of the expression product from the cell. The leader sequence may therefore be any pro-, pre- or prepro-sequence operable in the Pichia host. Usually, but not necessarily, however, the immunoglobulin single variable domains and / or polypeptides of the invention will have at least one transport signal that directs the immunoglobulin single variable domains and / or proteins of the invention to the periplasm. For example, leader sequences known per se for the expression and production of antibodies and antibody fragments, including but not limited to single domain antibodies and ScFv fragments, may be used in a substantially similar manner.

[0184] Some preferred, but non-limiting, secretory sequences include the α-mating factor signal sequence from Saccharomyces cerevisiae, the acid phosphatase (PHO1) signal sequence from P. pastoris, the phosphatase (pho1) leader sequence from P. pastoris, the yeast invertase secretion signal (Suc), the human serum albumin signal peptide, the GAM1 signal sequence from S. occidentalis, and the hyperglycemic hormone (CHH) sequence from Carcinus maenas.

[0185] The skilled artisan may also envisage the use of predicted signal peptides derived from genome sequencing experiments. These predicted signal peptide sequences may originate from any species, but are preferably of yeast origin, most preferably from yeasts from Saccharomyces, such as yeasts from the genus Saccharomyces, Komagataella, or Pichia (Hansenula), such as Saccharomyces cerevisiae or Pichia pastoris. Some preferred, but non-limiting, predicted signal peptides from P. pastoris are described in De Schutter et al. 2009 (Nature Biotech 27(6): 561-566). For the use of such predicted signal peptides for the production of immunoglobulin single variable domains, further reference is made to WO 2012 / 152823.

[0186] Also, known or predicted secretion sequences may be modified to improve the properties of the immunoglobulin single variable domains and / or polypeptides of the invention produced. Such modifications may improve the purity of the immunoglobulin single variable domains and / or polypeptides of the invention, for example by improving processing efficiency. Modifications of α-mating factor signal sequences to improve processing efficiency are described, for example, in WO 2012 / 152823.

[0187] The expression marker or reporter gene should be such that it allows detection of the expression of the genetic construct (the gene or nucleotide sequence present thereon) in the Pichia host. Such reporter genes may also be expressed as protein fusions with the immunoglobulin single variable domains and / or polypeptides of the invention. Some preferred, but non-limiting examples include fluorescent proteins, such as GFP and luciferase (LUC).

[0188] A genetic construct of the invention may generally be provided by suitably linking the nucleic acid and / or nucleotide sequence(s) of the invention to one or more further sequences as described above, using the techniques described in general handbooks such as Sambrook et al. and Ausubel et al., supra.

[0189] Often, the genetic construct of the invention will be obtained by inserting the nucleic acid or nucleotide sequence of the invention into a suitable (expression) vector known per se. Some preferred but non-limiting examples of suitable expression vectors are those used in the examples below, as well as those described herein.

[0190] Some preferred, but non-limiting, vectors for use in the genetic constructs of the present invention include vectors for expression in yeast or other fungal cells, such as pYES2 (Invitrogen), pUR3515 and pUR3501 (Sierkstra et al. 1991, Curr. Genet. 19: 81), and Pichia expression vectors, such as (but not limited to) pPICZ vectors, pPIC3.5, pPIC3.5K, pPIC6a, pPIC9, pPIC9K, pHIL-D2, pHIL-S1 for expression in P. pastoris, pMET, pMETα for expression in P. methanolica provided by Invitrogen. For a non-exhaustive list of Pichia expression vectors, see Daly and Hearn 2004 (J. Mol. Recognition 18: 119), Pichia Protocols 2007 (Ed. Cregg, 2 nd Ed., Humana Press, NJ) and Gelissen 2000 (Appl. Microbiol. Biotechnol. 54: 741).

[0191] The present invention also encompasses methods for the preparation of the nucleic acids and gene constructs of the invention comprising the step of cloning nucleotide sequences encoding the accessory protein gene(s) and / or the immunoglobulin single variable domains and / or polypeptides of the invention into a suitable vector.

[0192] The nucleic acids of the invention and / or the genetic constructs of the invention may be used to transform a Pichia host, i.e. for the expression and / or production of the immunoglobulin single variable domains and / or polypeptides of the invention. Suitable techniques for transforming a Pichia host will be apparent to the skilled artisan. Again, reference is made to the handbooks and patent applications mentioned above. For more details regarding transformation procedures, see the Invitrogen EasySelect™ Pichia Expression Manual, Wu and Letchworth 2004 (BioTechniques 36: 152), Pichia Protocols 2007 (Ed. Cregg, 2 nd Ed., Humana Press, NJ) and Faber 1994 (Curr. Genet. 25: 305). After transformation, steps can be carried out to detect and select Pichia host cells which have been successfully transformed with a nucleotide sequence / gene construct of the invention. This can be, for example, a selection step based on a selectable marker present in the gene construct of the invention, or a step involving detection of the amino acid sequence of the invention, for example using a specific antibody.

[0193] The present invention therefore further relates to the preparation of a Pichia host cell comprising a genetic construct or a nucleic acid of the invention. The skilled person can introduce the nucleic acid or genetic construct of the invention into a Pichia host by routine procedures, for example by transformation. The skilled person can then select a suitable Pichia host cell comprising the nucleic acid or genetic construct, for example by monitoring the expression of the auxiliary protein at the nucleic acid level and / or protein level. Strains with satisfactory expression levels will be selected. A high expression of the auxiliary protein is desirable, but should not be so high as to compete with the expression of the immunoglobulin single variable domains and / or polypeptides of the invention. This can be determined by routine methods.

[0194] Transformed Pichia host cells, which may be in the form of stable cell lines, form a further aspect of the present invention.

[0195] Pichia host Thus, the present invention also relates to a Pichia host comprising such a genetic construct or nucleic acid as described above. The terms "Pichia host" and "Pichia host cell" are used interchangeably and refer to yeasts of the genus Pichia (Hansenula and Hyphopichia are obsolete synonyms) of the family Saccharomycetaceae, which have spherical, elliptical, or oblong acuminate cells. Pichia are teleomorphs, which form cap-shaped, hemispherical, or round ascospores during sexual reproduction. The asexual generation of some Pichia species is Candida species. Asexual reproduction is by multiple lateral budding.

[0196] The present invention relates to, but is not limited to, Pichia hosts, provided that they are suitable for the production of immunoglobulin single variable domains and / or polypeptides comprising same. For purposes of the present invention, the term "Pichia host" also includes Hansenula species and Candida species.

[0197] A Pichia host of the invention will be capable of producing the immunoglobulin single variable domains and / or polypeptides of the invention and the HAC1 splice form protein, and optionally one or more additional auxiliary protein(s), such as protein disulfide isomerase (PDI1), Kar2p or conserved ribosomal protein P0 (RPP0). It will typically be genetically modified such that it comprises one or more nucleic acids encoding the immunoglobulin single variable domains and / or polypeptides of the invention, and such that expression of the HAC1 splice form protein is enhanced. Non-limiting examples of genetic modifications include transformation, for example with a plasmid or vector, or transduction, for example with a viral vector. Some hosts may be genetically modified by fusion techniques. Genetic modifications include the introduction of separate nucleic acid molecules, for example a plasmid or vector, into the host, as well as direct modification of the host's genetic material, for example by integration into the host's chromosome, for example by homologous recombination. Often a combination of both occurs, for example when the host is transformed with a plasmid, this plasmid will be integrated (at least in part) into the host's chromosome by homologous recombination. The person skilled in the art knows how to genetically modify the host appropriately to enable it to produce the immunoglobulin single variable domains and / or polypeptides of the invention.

[0198] Suitable Pichia hosts will be apparent to those skilled in the art and may be, for example, Pichia, Hansenula, or Candida, including, but not limited to, methanotrophic yeasts such as Pichia pastoris, Pichia methanolica, Hansenula polymorpha (Pichia angusta), and Candida boidinii. For a non-exhaustive list of Pichia strains, see, for example, Gelissen 2000 (Appl. Microbiol. Biotechno. 54: 741). Without limitation, P. pastoris strains may be selected from the group consisting of Pichia, Hansenula ... nd Ed., Humana Press, NJ). Examples of P. pastoris strains include (but are not limited to) X33, GS115, KM71, KM71H, SMD1163, SMD1165, SMD1168, SMD1168H, NRRL-Y11430, GS200 provided by Invitrogen and described by Cereghino and Cregg 2004 (FEMS Microbiol. Rev. 24: 45), by Macauley-Patrick et al. 2005 (Yeast 22: 249) and / or Damasceno et al. 2007 (Appl. Microbiol. Biotechno. 74: 381).

[0199] Examples of Hansenula polymorpha strains include (but are not limited to) A16 (Veale et al. 1992, Yeast 8: 361), GF16 (Faber 1994, Proc. Natl. Acad. Sci. USA 91: 12985), CBS4732 (CCY38-22-2; ATCC34438, NRRL-Y-5445), DL-1 (NRRL-Y-7560; ATCC26012), and NCYC495 strains (CBS1976; ATAA14754, NRLL-Y-1798).

[0200] Examples of P. methanolica strains include (but are not limited to) PMAD11 and PMAD16 provided by Invitrogen Corp. P. methanolica strains (IAM12901 and IAM12481) and C. boidinii strain (IAM12875) are described by Nakagawa et al. 1996 (J. Fermentation Bioeng. 81: 498).

[0201] Reference is also made to the general background art cited herein above, as well as, for example, WO 94 / 29457, Frenken et al. 1998 (Res. Immunol. 149: 589), van der Linden 2000 (J. Biotechnol. 80: 261), Joosten et al. 2003 (Microb. Cell Fact. 2: 1) and further literature cited therein.

[0202] For industrial scale production, preferred heterologous hosts for (industrial) production of protein therapeutics containing immunoglobulin single variable domains include Pichia pastoris strains, which are suitable for large scale expression / production / fermentation, in particular large scale pharmaceutical expression / production / fermentation. Suitable examples of such strains will be clear to the skilled artisan. Such strains and production / expression systems are also made available by companies such as Avecia Biologics (Billingham, North East England, UK), Biomeva GmbH (Heidelberg, Germany), PharmedArtis GmbH (Aachen, Germany), Richter-Helm (Hamburg, Germany) and CMC Biologics (Copenhagen, Denmark).

[0203] The present invention also includes further generations, progeny, and / or descendants of the Pichia host cells of the present invention, which may be obtained, for example, by cell division.

[0204] Pharmaceutical Preparations The present invention also relates to immunoglobulin single variable domains and / or polypeptides of the invention obtainable by the methods of the invention as described herein.

[0205] The present invention therefore also relates to pharmaceutical preparations and other compositions comprising the immunoglobulin single variable domains and / or polypeptides of the invention obtainable by the method of the invention.The present invention also relates to the medical use of the immunoglobulin single variable domains and / or polypeptides of the invention obtainable by the method of the invention.

[0206] A person skilled in the art can easily formulate a pharma- ceutically suitable formulation based on general knowledge. Moreover, explicit reference is made to the documents specifically dealing with immunoglobulin single variable domains and / or nanobodies cited herein. Formulations for standard routes of application may be prepared, including, but not limited to, formulations for intranasal, buccal, intravenous, subcutaneous, intramuscular, intraperitoneal, intravaginal, rectal, topical or inhalation application.

[0207] Based on the present invention, the skilled artisan can also easily devise a suitable treatment regimen, characterized by the use of a therapeutically effective amount of the immunoglobulin single variable domains and / or polypeptides of the invention obtainable by the methods of the invention.

[0208] The present invention is further illustrated by the following examples, which should not be construed as further limiting in any way. The entire contents of all documents cited throughout this application (including literature references, issued patents, published patent applications, and co-pending patent applications) are expressly incorporated herein by reference, particularly for the teachings referenced herein above.

[0209] Working Example The experimental section describes the surprisingly low yields observed upon expression of monovalent and polyvalent immunoglobulin single variable domains in Pichia pastoris. The inventors also observed that the yields were further reduced when more than one copy of the expression cassette was present in the genome of P. pastoris. Also described is a method for increasing the expression yield of the immunoglobulin single variable domains by enhancing the expression of the HAC1 splice form.

[0210] Example 1: Identification of accessory proteins that increase the expression of nanobodies in Pichia pastoris 1.1 Construction of expression vector Nanobody A, previously described in WO 2013 / 045707 as SEQ ID NO: 7, is a bivalent nanobody consisting of two sequence-optimized variable domains of a heavy chain llama antibody. The N-terminal subunit in Nanobody A is a VHH1-type immunoglobulin single variable domain and is specific for binding to c-Met, whereas the C-terminal subunit binds human serum albumin (HSA). The subunits are fused head to tail using a 9G / S linker. The sequence of Nanobody A (SEQ ID NO: 49) is shown in Table A-1. Nanobody A was previously shown to give very low yields (0.2 g / L or less) when fermented in P. pastoris.

[0211] A DNA fragment containing the coding information for Nanobody A was cloned into the multiple cloning site of a Pichia expression vector (a derivative of pPIC6a, Invitrogen) containing a Blasticidin™ resistance genetic marker, such that the Nanobody sequence was downstream and in frame with the aMF signal peptide sequence. To generate Pichia clones with more than one copy of the expression cassette in the genome, a unique BglII site in the Pichia expression vector was used to introduce a second expression cassette for Nanobody A.

[0212] The coding sequences of the auxiliary proteins shown in Table A-2 were cloned (using the restriction enzymes BstBI and NotI) into a Pichia expression vector (derivative of pPICZa, Invitrogen) containing a Zeocin™ resistance genetic marker. The auxiliary proteins containing a BstBI site within their coding sequence were cloned using the restriction enzymes AfeI and NotI. Both the nanobodies and the auxiliary proteins in the pPIC6a and pPICZa vectors were under the control of the AOX1 methanol-inducible promoter.

[0213] 1.2 Transformation of Nanobody coding sequences and expression and secretion of the Nanobodies in Pichia hosts Transformation and expression studies of wild-type Pichia X33 were performed by standard techniques and according to the "User manual for pPicZalphaA, B and C" (version D, 110801, manual part number 25-0148: Invitrogen Corporation) and Methods in Molecular Biology 2007 (Humana Press Inc.). First, P. pastoris strains were transformed with the appropriate expression vectors carrying a single or two expression cassettes of Nanobody A. Transformants were grown on selection medium containing Blasticidin™. Many individual colonies were characterized by qPCR to select clones with one copy of the expression vector integrated in the genome and clones with more than one copy of the expression cassette integrated in the genome. Expression and secretion of the Nanobody into the medium was confirmed (Figure 1).

[0214] 1.3 Transformation of auxiliary protein coding sequences and expression and secretion of nanobodies in Pichia pastoris Once colonies expressing the appropriate nanobody were identified, the inoculum was expanded and prepared as competent cells. These cells were then transformed with an expression vector library containing the 22 auxiliary proteins shown in Table A-2. The transformants were grown on selective media containing various selection markers (Zeocin™), thus obtaining co-transformants containing both the nanobody of interest and one or more auxiliary proteins of Table A-2. Expression in shake flasks was performed in 5 mL cultures of BMCM medium and induced by addition of methanol as described in the Pichia protocol (see, for example, Methods in molecular biology 2007, Humana Press Inc.).

[0215] In each setting, 1128 clones were screened for improved expression and compared to their corresponding reference clones containing only one or more copies of the Nanobody expression cassette integrated into the genome, but no expression vectors encoding one or more auxiliary proteins. In each setting, we found two clones with significantly higher yields than their reference clones. Clones 6H1 and 4C2 had one copy of the Nanobody coding sequence integrated into the genome (copy number = 1), and clones 5A6 and 9C4 had more than one copy of the Nanobody coding sequence integrated into the genome (copy number > 1) (Figure 2).

[0216] 1.4 Identification of auxiliary proteins with positive effects on expression yield Identification of auxiliary proteins exerting a positive effect on the expression yield of nanobodies in P. pastoris was performed using genomic DNA PCR using sequence-specific PCR primers. The list of primers used is shown in Table A-3. The identified auxiliary proteins are shown in Table 1.

[0217] [Table 1]

[0218] 1.5 Determination of expression yields of various clones Expression yields of Nanobody / auxiliary protein(s) co-transformants were compared to those of controls in expression experiments (Nanobody transformants without enhanced expression of one or more auxiliary protein(s)) by quantification of the yield of Nanobody expressed and secreted into the medium. Standard fed-batch fermentation conditions were used. Glycerol fed-batch cultures were performed and induction was started by addition of methanol. Production was carried out at 2L scale at pH 6 and 30° C. in complex medium with a methanol feed rate of 4 ml / L / h.

[0219] Samples were subjected to SDS-PAGE analysis. Relative protein quantification was performed using densitometric scan measurements of Coomassie stained SDS-PAGE (Table 2).

[0220] [Table 2]

[0221] Clones 4C2 and 6H1 showed a significant increase in expression compared to their reference clones (one copy of the expression cassette integrated in the genome). This increase in expression was likely the result of co-expression of PDI1, which is present in both clones. Similarly, clones 5A6 and 9C4 showed a huge increase in yield compared to their reference clones. The auxiliary proteins expressed in both clones 5A6 and 9C4 are Kar2p, RPP0 and the HAC1 splice form. Such auxiliary proteins are most likely responsible for the improved expression of Nanobody A. Interestingly, the expression level of clone 4C2 was significantly higher than clone 6H1, likely the result of co-expression of Kar2p and the HAC1 splice form, which are also present in the highest expressing clones 5A6 and 9C4. All clones with the highest yields co-expressed the HAC1 splice form (Tables 1 and 2).

[0222] Example 2: Evaluation of Nanobody A yield upon enhanced expression of individual accessory proteins The individual auxiliary proteins PDI1, Kar2p, RPP0 and HAC1 splice forms were transformed into a reference clone carrying more than one copy of the Nanobody expression cassette in the genome as described in Example 1.3. Transformants were grown on selective medium containing Zeocin™. Co-transformants were obtained containing both Nanobody A and the specific auxiliary protein. Expression in shake flasks was performed in 5 mL cultures of BMCM medium and induced by addition of methanol as described in the Pichia protocol (see, for example, Methods in molecular biology 2007, Humana Press Inc.). Relative quantification of the proteins was performed using densitometric scanning of Coomassie-stained SDS-PAGE (Figure 3). All clones co-expressing one of the auxiliary proteins showed a significant increase in the yield of Nanobody A. Again, we observed that the clones containing the HAC1 splice form showed the greatest improvement in yield.

[0223] Example 3: Evaluation of Nanobody B yield upon enhanced expression of individual accessory proteins 3.1 Construction of expression vector Nanobody B is a trivalent nanobody consisting of three sequence-optimized variable domains of a heavy chain llama antibody. The subunits in Nanobody B are not VHH1-type immunoglobulin single variable domains and do not bind human serum albumin (HSA). The subunits are fused head-to-tail using a 35G / S linker. Nanobody B was shown to give very low yields (0.29 g / L or less) when fermented in P. pastoris.

[0224] A DNA fragment containing the coding information for Nanobody B was cloned into the multiple cloning site of a Pichia expression vector (a derivative of pPpT4_Alpha_S: Naatsaari et al. 2012, PLoS One 7: e39720) containing a Zeocin™ resistance genetic marker, such that the Nanobody sequence was downstream and in frame with the aMF signal peptide sequence. The coding sequences for the auxiliary proteins HAC1 splice form, Kar2p, PDI1 and RPP0 were cloned into a Pichia expression vector containing a Blasticidin™ resistance genetic marker. Both the Nanobody and the auxiliary proteins were under the control of the AOX1 methanol inducible promoter.

[0225] 3.2 Transformation The individual accessory protein PDI1, Kar2p, RPP0 and HAC1 splice forms were transformed into Pichia pastoris strain NRRL Y-11430 (ATCC number 76273). Transformants were grown on selection medium containing Blasticidin™. Single clones were isolated and subsequently transformed with Nanobody B.

[0226] 3.3 Determination of expression yields of individual clones Expression analysis was performed as described in Example 1.5. Relative quantification of proteins was performed using densitometric scan of Coomassie stained SDS-PAGE (Table 3). Only clones co-expressing the HAC1 splice form of the auxiliary protein showed a large increase in the yield of Nanobody B, again indicating that enhanced expression of the HAC1 splice form of the auxiliary protein most effectively improves the yield.

[0227] [Table 3]

[0228] Example 4: Evaluation of the yield of well-expressed Nanobody C with enhanced expression of individual auxiliary proteins Nanobody C is a bivalent nanobody consisting of two sequence-optimized variable domains of a heavy chain llama antibody. No subunit in Nanobody C is a VHH1-type immunoglobulin single variable domain. The C-terminal subunit binds human serum albumin (HSA). The subunits are head-to-tail fused using a 35G / S linker. The individual accessory protein PDI1, Kar2p, RPP0 and HAC1 splice forms were cloned as described in Example 3 and transformed into Pichia pastoris strain NRRL Y-11430. Transformants were grown on selective medium containing Blasticidin™. Single clones were isolated and subsequently transformed with Nanobody C. Expression analysis was performed as described in Example 1.5. Relative quantification of proteins was performed using densitometric scanning of Coomassie-stained SDS-PAGE (Table 4).

[0229] Only clones co-expressing the HAC1 splice form and auxiliary proteins showed a significant increase in the yield of Nanobody C, indicating again that enhanced expression of the HAC1 splice form of the auxiliary proteins is most effective in improving the yield of the Nanobody, indicating that enhanced expression of the HAC1 splice form of the auxiliary proteins can also increase the yield of well-expressing Nanobodies.

[0230] [Table 4]

[0231] Example 5: Evaluation of the expression yield of different Nanobodies (Nanobody D, Nanobody E, Nanobody F, Nanobody G and Nanobody H) upon enhanced expression of the HAC1 splice forms of accessory proteins Nanobody D is a bivalent nanobody consisting of two sequence-optimized variable domains of a heavy chain llama antibody. The N-terminal subunit in Nanobody D is a VHH1-type immunoglobulin single variable domain specific for binding to c-Met, whereas the C-terminal subunit binds human serum albumin (HSA). The subunits are fused head-to-tail with a 9G / S linker and contain a C-terminal Flag3-His6 epitope tag. The sequence of Nanobody D (SEQ ID NO: 50) is shown in Table A-1. Nanobody E is a trivalent nanobody consisting of three sequence-optimized variable domains of a heavy chain llama antibody. The C-terminal subunit in Nanobody E is a VHH1-type immunoglobulin single variable domain, whereas the central subunit binds human serum albumin (HSA). The subunits are fused head-to-tail with a G / S linker and contain a C-terminal Flag3-His6 epitope tag. The sequence of Nanobody E (SEQ ID NO: 51) is shown in Table A-1. Nanobody F is a trivalent Nanobody consisting of three sequence-optimized variable domains of a heavy chain llama antibody. The C-terminal subunit in Nanobody F is a VHH1-type immunoglobulin single variable domain. The subunit in Nanobody F does not bind human serum albumin (HSA). The subunit is fused head-to-tail with a 35G / S linker and contains a C-terminal Flag3-His6 epitope tag. The sequence of Nanobody F (SEQ ID NO: 52) is shown in Table A-1. Nanobodies G and H are tetravalent Nanobodies consisting of four sequence-optimized variable domains of a heavy chain llama antibody. The C-terminal subunit in Nanobody G and H is a VHH1-type immunoglobulin single variable domain, while one of the central subunits binds human serum albumin (HSA). The subunit is fused head-to-tail with a 35G / S linker. The sequences of Nanobodies G and H (SEQ ID NO: 53 and SEQ ID NO: 54, respectively) are shown in Table A-1. Nanobody I is a monovalent Nanobody that specifically binds to TNF. Nanobody I consists essentially of an optimized variable domain of one sequence, further comprising one alanine residue as a C-terminal extension. Nanobody I is not a VHH1-type immunoglobulin single variable domain. The sequence of Nanobody I (SEQ ID NO: 55) is shown in Table A-1.

[0232] The HAC1 splice forms of the individual auxiliary proteins were cloned as described in 3.1 and transformed into Pichia pastoris strain NRRL Y-11430. Transformants were grown on selection medium containing Blasticidin™. Single clones were isolated and subsequently transformed with Nanobodies D, E, F, G or H. Expression analysis was performed as described in Example 1.5. Relative protein quantification was performed using densitometric scanning of Coomassie stained SDS-PAGE (Table 5). Enhanced expression of the HAC1 splice forms of the auxiliary proteins improved the yield of all nanobodies. This again demonstrates that enhanced expression of the HAC1 splice forms of the auxiliary proteins effectively improves the yield of nanobodies.

[0233] [Table 5]

[0234] [Table 6] TIFF2024073531000014.tif64165

[0235] [Table 7] TIFF2024073531000016.tif203165 TIFF2024073531000017.tif249165 TIFF2024073531000018.tif225165 TIFF2024073531000019.tif249165

[0236] [Table 8]

[0237]

Table 9

Claims

1. 1. A method for producing a polypeptide comprising or consisting of at least one immunoglobulin single variable domain, the method comprising expressing said polypeptide in a Pichia host and simultaneously enhancing expression of an accessory protein HAC1 splice form (SEQ ID NO: 14) in said Pichia host, wherein said at least one immunoglobulin single variable domain is a heavy chain variable domain or a fragment thereof.

2. The method of claim 1 further comprising the step of isolating and / or purifying the polypeptide.

3. 3. The method of claim 1 or 2, further comprising the step of formulating the polypeptide in a buffer.

4. The method of any of claims 1 to 3, further comprising the step of formulating the polypeptide as a pharmaceutical composition.

5. 1. A Pichia host which expresses, or is capable under suitable circumstances of expressing, a polypeptide comprising or consisting of at least one immunoglobulin single variable domain, wherein expression of the accessory protein HAC1 splice form (SEQ ID NO: 14) is enhanced, and wherein the at least one immunoglobulin single variable domain is a heavy chain variable domain or a fragment thereof.

6. The method according to any one of claims 1 to 4 or the Pichia host according to claim 5, wherein the expression of the HAC1 splice form protein is enhanced by the introduction into the Pichia host of one or more nucleic acids encoding the -HAC1 splice form protein; and / or one or more strong promoters controlling the expression of the nucleic acids encoding the -HAC1 splice form protein.

7. 7. The method or Pichia host of claim 6, wherein the polypeptide comprising or consisting of at least one immunoglobulin single variable domain and the HAC1 splice form protein are expressed from the same genetic construct.

8. 8. The method or Pichia host of claim 7, wherein the nucleic acid encoding the HAC1 splice form protein is located on a genetic construct downstream of a nucleic acid encoding a polypeptide comprising or consisting of at least one immunoglobulin single variable domain.

9. 9. The method or Pichia host according to claim 7 or 8, wherein the transcription of the nucleic acid encoding the polypeptide comprising or consisting of at least one immunoglobulin single variable domain and the transcription of the nucleic acid encoding the HAC1 splice form protein are controlled by the same promoter.

10. 9. The method or Pichia host according to claim 7 or 8, wherein the transcription of the nucleic acid encoding the polypeptide comprising or consisting of at least one immunoglobulin single variable domain and the transcription of the nucleic acid encoding the HAC1 splice form protein are controlled by different promoters.

11. 7. The method or Pichia host of claim 6, wherein the polypeptide comprising or consisting of at least one immunoglobulin single variable domain and the HAC1 splice form protein are expressed from different gene constructs.

12. 12. The method or Pichia host of claim 11, wherein the transcription of the nucleic acid encoding the polypeptide comprising or consisting of at least one immunoglobulin single variable domain and the transcription of the nucleic acid encoding the HAC1 splice form protein from the different genetic constructs are controlled by the same separate promoter.

13. 12. The method or Pichia host of claim 11, wherein the transcription of the nucleic acid encoding the polypeptide comprising or consisting of at least one immunoglobulin single variable domain and the transcription of the nucleic acid encoding the HAC1 splice form protein from the different genetic constructs are controlled by different and separate promoters.

14. The method or Pichia host according to any of claims 6 to 13, wherein the polypeptide comprising or consisting of at least one immunoglobulin single variable domain and / or the HAC1 splice form protein is expressed from a chromosome.

15. 15. The method or Pichia host of claim 14, wherein expression of the HAC1 splice form protein is enhanced by introduction of a strong promoter into the chromosome of the Pichia host.

16. 15. The method or Pichia host of claim 14, wherein one or more nucleic acids encoding a HAC1 splice form protein controlled by a strong promoter are introduced into the chromosome of the Pichia host.

17. 15. The method or Pichia host of claim 14, wherein one or more nucleic acids encoding a polypeptide comprising or consisting of at least one immunoglobulin single variable domain are introduced into a chromosome of the Pichia host.

18. The method or Pichia host according to any of claims 1 to 17, wherein the copy number of the nucleic acid encoding a polypeptide comprising or consisting of at least one immunoglobulin single variable domain is one.

19. The method or Pichia host according to any of claims 1 to 17, wherein the copy number of the nucleic acid encoding a polypeptide comprising or consisting of at least one immunoglobulin single variable domain is two or more.

20. The method or Pichia host according to any one of claims 1 to 19, wherein the Pichia host is Pichia pastoris.

21. 21. The method or Pichia host of claim 20, wherein the Pichia pastoris strain is selected from X33 and NRRL Y-11430.

22. 1. A nucleic acid encoding a polypeptide comprising or consisting of at least one immunoglobulin single variable domain and encoding the HAC1 splice form (SEQ ID NO: 14), wherein said at least one immunoglobulin single variable domain is a heavy chain variable domain or a fragment thereof.

23. 23. The nucleic acid of claim 22 in the form of a genetic construct.

24. 1. A genetic construct comprising a nucleic acid encoding a polypeptide comprising or consisting of at least one immunoglobulin single variable domain and a nucleic acid encoding the HAC1 splice form (SEQ ID NO: 14), wherein said at least one immunoglobulin single variable domain is a heavy chain variable domain or a fragment thereof.

25. 25. A genetic construct according to claim 24, wherein the nucleic acid encoding the HAC1 splice form protein is located downstream of the nucleic acid encoding a polypeptide comprising or consisting of at least one immunoglobulin single variable domain.

26. 26. A genetic construct according to claim 24 or 25, wherein the expression of the nucleic acid encoding the polypeptide comprising or consisting of at least one immunoglobulin single variable domain and the expression of the nucleic acid encoding the HAC1 splice form protein are controlled by the same promoter.

27. 26. A genetic construct according to claim 24 or 25, wherein the expression of the nucleic acid encoding the polypeptide comprising or consisting of at least one immunoglobulin single variable domain and the expression of the nucleic acid encoding the HAC1 splice form protein are controlled by different promoters.

28. A Pichia host according to any one of claims 5 to 21, comprising a genetic construct according to any one of claims 24 to 27.

29. 29. The method, nucleic acid, genetic construct or Pichia host of any one of claims 1 to 28, wherein expression of one or more additional auxiliary proteins is enhanced.

30. 30. The method, nucleic acid, genetic construct or Pichia host of claim 29, wherein the additional auxiliary protein is selected from PDI1, Kar2p, and RPP0.

31. 31. The method, nucleic acid, genetic construct or Pichia host of claim 29 or 30, wherein the number of auxiliary proteins is two.

32. The two auxiliary proteins are the following combinations of two auxiliary proteins: - PDI1 (SEQ ID NO: 5) and HAC1 splice form (SEQ ID NO: 14); - Kar2p (SEQ ID NO: 4) and HAC1 splice form (SEQ ID NO: 14); and -RPP0 (SEQ ID NO: 6) and HAC1 splice form (SEQ ID NO: 14) 32. The method, nucleic acid, genetic construct, or Pichia host of claim 31 , selected from:

33. 31. The method, nucleic acid, genetic construct or Pichia host of claim 29 or 30, wherein the number of auxiliary proteins is three.

34. The three auxiliary proteins are the following combinations of three auxiliary proteins: - PDI1 (SEQ ID NO: 5), RPP0 (SEQ ID NO: 6) and HAC1 splice form (SEQ ID NO: 14); - Kar2p (SEQ ID NO: 4), RPP0 (SEQ ID NO: 6) and HAC1 splice form (SEQ ID NO: 14); and - PDI1 (SEQ ID NO: 5), Kar2p (SEQ ID NO: 4), and HAC1 splice form (SEQ ID NO: 14) 34. The method, nucleic acid, genetic construct, or Pichia host of claim 33, selected from the group consisting of:

35. 30. The method, nucleic acid, genetic construct or Pichia host of claim 29, wherein expression of PDI1 (SEQ ID NO:5), Kar2p (SEQ ID NO:4), RPP0 (SEQ ID NO:6) and HAC1 splice form (SEQ ID NO:14) is enhanced.

36. 36. The method, nucleic acid, genetic construct or Pichia host of any one of claims 1 to 35, wherein the polypeptide is a monovalent polypeptide.

37. 37. The method, nucleic acid, genetic construct or Pichia host according to claims 1 to 36, wherein the immunoglobulin single variable domain consists of four framework regions (FR1 to FR4, respectively) and three complementarity determining regions (CDR1 to CDR3, respectively), wherein CDR1 is SEQ ID NO: 58, CDR2 is SEQ ID NO: 60 and CDR3 is SEQ ID NO:

62.

38. 38. The method, nucleic acid, genetic construct or Pichia host according to claims 1 to 37, wherein the immunoglobulin single variable domain is SEQ ID NO:

56.

39. 39. The method, nucleic acid, genetic construct or Pichia host of any of claims 1 to 38, wherein the polypeptide further comprises one or more other residues or binding units, optionally linked via one or more peptide linkers.

40. 40. The method, nucleic acid, genetic construct or Pichia host of claim 39, wherein said one or more other residues or binding units are immunoglobulin single variable domains.

41. 41. The method, nucleic acid, genetic construct, or Pichia host of claim 39 or 40, wherein the polypeptide is a multivalent construct.

42. 42. The method, nucleic acid, genetic construct, or Pichia host of claim 41, wherein the polypeptide is a bivalent, trivalent, or tetravalent polypeptide.

43. 43. The method, nucleic acid, genetic construct or Pichia host of any of claims 39 to 42, wherein said one or more other binding units provide a polypeptide with an extended half-life compared to a polypeptide not comprising said one or more binding units.

44. 44. The method, nucleic acid, genetic construct or Pichia host of claim 43, wherein the one or more other binding units providing a polypeptide with an extended half-life are selected from the group consisting of binding units capable of binding to serum albumin (e.g. human serum albumin) or serum immunoglobulin (e.g. IgG).

45. 45. The method, nucleic acid, genetic construct, or Pichia host of claim 44, wherein the polypeptide comprises at least one immunoglobulin single variable domain that binds serum albumin.

46. 46. ​​The method, nucleic acid, genetic construct or Pichia host of any preceding claim, wherein the polypeptide further comprises a C-terminal extension X(n), where n is 1 to 5, such as 1, 2, 3, 4 or 5, and X is a naturally occurring amino acid, preferably not including any cysteine.

47. 47. The method, nucleic acid, genetic construct or Pichia host of any of claims 1 to 46, wherein the polypeptide comprises or consists of SEQ ID NO:

55.

48. 48. The method, nucleic acid, genetic construct or Pichia host of any of claims 1 to 47, wherein at least one immunoglobulin single variable domain is selected from a domain antibody, a single domain antibody, a "dAb", or an immunoglobulin single variable domain selected from a VHH, a humanized VHH, and a camelized heavy chain variable domain.

49. 49. The method, nucleic acid, genetic construct or Pichia host of claim 48, wherein at least one immunoglobulin single variable domain comprises two or more disulfide bridges.

50. 50. The method, nucleic acid, genetic construct or Pichia host of any of claims 39 to 49, wherein one or more of the binding units is selected from a domain antibody, a single domain antibody, a "dAb" or an immunoglobulin single variable domain selected from VHH, humanized VHH, and camelized heavy chain variable domains.

51. The method, nucleic acid, genetic construct, or Pichia host of claim 48 or 50, wherein the immunoglobulin single variable domain is selected from a VHH, a humanized VHH, and a camelized heavy chain variable domain.

52. 52. The method, nucleic acid, genetic construct or Pichia host according to claim 51 , wherein the VHH belongs to the group of VHH1 type immunoglobulin single variable domains.

53. 53. The method, nucleic acid, genetic construct or Pichia host of any of claims 1-52, wherein the polypeptide is selected from a group of polypeptides whose yield when expressed in a Pichia host under standard Pichia expression conditions correlates inversely with the copy number of the nucleic acid encoding said polypeptide in the Pichia host.

54. 54. A polypeptide comprising or consisting of at least one immunoglobulin single variable domain obtainable by any of the methods of claims 1 to 4, 6 to 21 or 29 to 53, wherein said at least one immunoglobulin single variable domain is a heavy chain variable domain or a fragment thereof.

55. A pharmaceutical composition comprising the polypeptide of claim 54.